[{"type_of_evidence": "Predictive / Therapeutic", "drugs": ["Carfilzomib", "Vorinostat"], "interactions": [], "effect": "Sensitive (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Sensitivity to  carfilzomib and vorinostat (also called SAHA) was tested in the triple-negative  breast cancer cell line HCC-1395.", "support": "Low", "comment": null, "references": "PMID:27347849", "annotations": [], "created_on": "2020-05-19T17:45:41.842Z", "last_modified": "2020-05-26T14:28:07.268Z", "status": "draft", "request_id": null, "disease": {"name": "Carcinoma of breast", "localization": "BREAST", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R175H", "hgvs_c": "NM_000546.5:c.524G>A", "hgvs_p": "NP_000537.3:p.Arg175His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7578406, "dbsnp_ids": ["28934578"]}, "extra_variants": []}, {"type_of_evidence": "Function", "drugs": [], "interactions": [], "effect": "Neomorphic", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "In breast cancer cell line MDA-MB-231, variant R175H, through its association with NRF2/NFE2L2,  increases proteasome gene transcription.", "support": "Strong", "comment": null, "references": "PMID:27347849", "annotations": [], "created_on": "2020-05-19T17:06:04.268Z", "last_modified": "2020-05-26T13:02:44.240Z", "status": "draft", "request_id": null, "disease": {"name": "Carcinoma of breast", "localization": "BREAST", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R175H", "hgvs_c": "NM_000546.5:c.524G>A", "hgvs_p": "NP_000537.3:p.Arg175His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7578406, "dbsnp_ids": ["28934578"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["nutlin-3a"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Experiments were done in  MOLM-13 cell line (that the authors claim as being an AML cell line) expressing R175H mutation.", "support": "Moderate", "comment": "", "references": "PMID:31395785", "annotations": [], "created_on": "2020-05-19T14:25:58.097Z", "last_modified": "2020-05-22T14:24:52.101Z", "status": "draft", "request_id": null, "disease": {"name": "Acute myeloid leukemia, disease", "localization": "LEUKEMIA", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R175H", "hgvs_c": "NM_000546.5:c.524G>A", "hgvs_p": "NP_000537.3:p.Arg175His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7578406, "dbsnp_ids": ["28934578"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["etoposide"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Experiments were done in  MOLM-13 cell line (that the authors claim as being an AML cell line) expressing R175H mutation.", "support": "Moderate", "comment": "", "references": "PMID:31395785", "annotations": [], "created_on": "2020-05-19T14:12:55.060Z", "last_modified": "2020-05-22T14:24:54.895Z", "status": "draft", "request_id": null, "disease": {"name": "Acute myeloid leukemia, disease", "localization": "LEUKEMIA", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R175H", "hgvs_c": "NM_000546.5:c.524G>A", "hgvs_p": "NP_000537.3:p.Arg175His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7578406, "dbsnp_ids": ["28934578"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["Cytarabine"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Experiments were done in  MOLM-13 cell line (that the authors claim as being an AML cell line) expressing R248Q mutation.", "support": "Moderate", "comment": null, "references": "PMID:31395785", "annotations": [], "created_on": "2020-05-22T14:30:18.802Z", "last_modified": "2020-05-22T14:30:18.802Z", "status": "draft", "request_id": null, "disease": {"name": "Acute myeloid leukemia, disease", "localization": "LEUKEMIA", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R248Q", "hgvs_c": "NM_000546.5:c.743G>A", "hgvs_p": "NP_000537.3:p.Arg248Gln", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577538, "dbsnp_ids": ["11540652"]}, "extra_variants": []}, {"type_of_evidence": "Prognostic", "drugs": [], "interactions": [], "effect": "Poor outcome", "tier_level_criteria": "Population study", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Breast cancer patients who harbor R273C mutation have worse overall survival than those with wild type TP53, but have better prognosis than those with R248W mutation.", "support": "Moderate", "comment": null, "references": "PMID:16489069", "annotations": [], "created_on": "2020-05-26T17:46:45.330Z", "last_modified": "2020-05-27T09:34:50.990Z", "status": "draft", "request_id": null, "disease": {"name": "Carcinoma of breast", "localization": "BREAST", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R273C", "hgvs_c": "NM_000546.5:c.817C>T", "hgvs_p": "NP_000537.3:p.Arg273Cys", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577121, "dbsnp_ids": ["121913343"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["daunorubicin"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Experiments were done in  MOLM-13 cell line (that the authors claim as being an AML cell line) expressing R175H mutation.", "support": "Moderate", "comment": null, "references": "PMID:31395785", "annotations": [], "created_on": "2020-05-19T14:10:49.015Z", "last_modified": "2020-05-22T14:24:43.834Z", "status": "draft", "request_id": null, "disease": {"name": "Acute myeloid leukemia, disease", "localization": "LEUKEMIA", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R175H", "hgvs_c": "NM_000546.5:c.524G>A", "hgvs_p": "NP_000537.3:p.Arg175His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7578406, "dbsnp_ids": ["28934578"]}, "extra_variants": []}, {"type_of_evidence": "Subcellular location", "drugs": [], "interactions": [], "effect": "Unaltered location", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Variant R248Q is located within the nucleus.", "support": "Strong", "comment": null, "references": "PMID:21187651", "annotations": [], "created_on": "2020-06-11T11:43:35.833Z", "last_modified": "2020-06-11T11:43:35.833Z", "status": "draft", "request_id": null, "disease": null, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R248Q", "hgvs_c": "NM_000546.5:c.743G>A", "hgvs_p": "NP_000537.3:p.Arg248Gln", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577538, "dbsnp_ids": ["11540652"]}, "extra_variants": []}, {"type_of_evidence": "Prognostic", "drugs": [], "interactions": [], "effect": "Poor outcome", "tier_level_criteria": "Population study", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Breast cancer patients who harbor R175H mutation have worse overall survival than those with wild type TP53, but have better prognosis than those with R248W mutation.", "support": "Moderate", "comment": null, "references": "PMID:16489069", "annotations": [], "created_on": "2020-05-19T16:42:43.422Z", "last_modified": "2020-05-26T17:46:57.387Z", "status": "draft", "request_id": null, "disease": {"name": "Carcinoma of breast", "localization": "BREAST", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R175H", "hgvs_c": "NM_000546.5:c.524G>A", "hgvs_p": "NP_000537.3:p.Arg175His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7578406, "dbsnp_ids": ["28934578"]}, "extra_variants": []}, {"type_of_evidence": "Interaction", "drugs": [], "interactions": ["NFE2L2"], "effect": "New interaction partner(s)", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "In MDA-MB-231 cell line and other cell lines, variant R175H, but not wild-type TP53, interacts with NFE2L2 (also called NRF2).", "support": "Strong", "comment": null, "references": "PMID:27347849", "annotations": [], "created_on": "2020-05-19T17:18:47.106Z", "last_modified": "2020-05-26T13:54:22.915Z", "status": "draft", "request_id": null, "disease": {"name": "Carcinoma of breast", "localization": "BREAST", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R175H", "hgvs_c": "NM_000546.5:c.524G>A", "hgvs_p": "NP_000537.3:p.Arg175His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7578406, "dbsnp_ids": ["28934578"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["Cytarabine"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Experiments were done in  MOLM-13 cell line (that the authors claim as being an AML cell line) expressing R175H mutation.", "support": "Moderate", "comment": "", "references": "PMID:31395785", "annotations": [], "created_on": "2020-05-19T14:08:48.712Z", "last_modified": "2020-05-22T14:24:41.120Z", "status": "draft", "request_id": null, "disease": {"name": "Acute myeloid leukemia, disease", "localization": "LEUKEMIA", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R175H", "hgvs_c": "NM_000546.5:c.524G>A", "hgvs_p": "NP_000537.3:p.Arg175His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7578406, "dbsnp_ids": ["28934578"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["mitoxantrone"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": null, "support": "Moderate", "comment": "Experiments were done in  MOLM-13 cell line (that the authors claim as being an AML cell line) expressing R175H mutation.", "references": "PMID:31395785", "annotations": [], "created_on": "2020-05-19T14:24:22.045Z", "last_modified": "2020-05-22T14:24:50.007Z", "status": "draft", "request_id": null, "disease": {"name": "Acute myeloid leukemia, disease", "localization": "LEUKEMIA", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R175H", "hgvs_c": "NM_000546.5:c.524G>A", "hgvs_p": "NP_000537.3:p.Arg175His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7578406, "dbsnp_ids": ["28934578"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["mitoxantrone"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Experiments were done in  MOLM-13 cell line (that the authors claim as being an AML cell line) expressing R248Q mutation.", "support": "Moderate", "comment": null, "references": "PMID:31395785", "annotations": [], "created_on": "2020-05-22T14:31:36.118Z", "last_modified": "2020-05-22T14:31:36.118Z", "status": "draft", "request_id": null, "disease": {"name": "Acute myeloid leukemia, disease", "localization": "LEUKEMIA", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R248Q", "hgvs_c": "NM_000546.5:c.743G>A", "hgvs_p": "NP_000537.3:p.Arg248Gln", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577538, "dbsnp_ids": ["11540652"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["daunorubucin"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Experiments were done in  MOLM-13 cell line (that the authors claim as being an AML cell line) expressing R273H mutation.", "support": "Moderate", "comment": null, "references": "PMID:31395785", "annotations": [], "created_on": "2020-05-22T14:35:30.317Z", "last_modified": "2020-05-22T14:35:30.318Z", "status": "draft", "request_id": null, "disease": {"name": "Acute myeloid leukemia, disease", "localization": "LEUKEMIA", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R273H", "hgvs_c": "NM_000546.5:c.818G>A", "hgvs_p": "NP_000537.3:p.Arg273His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577120, "dbsnp_ids": ["28934576"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["Carfilzomib"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Resistance to carfilzomib  alone was tested in HCC-1395 cell line.", "support": "Low", "comment": null, "references": "PMID:27347849", "annotations": [], "created_on": "2020-05-19T17:40:43.318Z", "last_modified": "2020-05-26T14:01:48.690Z", "status": "draft", "request_id": null, "disease": {"name": "Carcinoma of breast", "localization": "BREAST", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R175H", "hgvs_c": "NM_000546.5:c.524G>A", "hgvs_p": "NP_000537.3:p.Arg175His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7578406, "dbsnp_ids": ["28934578"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["nutlin-3a"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Experiments were done in  MOLM-13 cell line (that the authors claim as being an AML cell line) expressing R248Q mutation.", "support": "Moderate", "comment": null, "references": "PMID:31395785", "annotations": [], "created_on": "2020-05-22T14:27:10.539Z", "last_modified": "2020-05-22T14:27:10.539Z", "status": "draft", "request_id": null, "disease": {"name": "Acute myeloid leukemia, disease", "localization": "LEUKEMIA", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R248Q", "hgvs_c": "NM_000546.5:c.743G>A", "hgvs_p": "NP_000537.3:p.Arg248Gln", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577538, "dbsnp_ids": ["11540652"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["etoposide"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Experiments were done in  MOLM-13 cell line (that the authors claim as being an AML cell line) expressing R248Q mutation.", "support": "Moderate", "comment": null, "references": "PMID:31395785", "annotations": [], "created_on": "2020-05-22T14:32:33.125Z", "last_modified": "2020-05-22T14:32:33.126Z", "status": "draft", "request_id": null, "disease": {"name": "Acute myeloid leukemia, disease", "localization": "LEUKEMIA", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R248Q", "hgvs_c": "NM_000546.5:c.743G>A", "hgvs_p": "NP_000537.3:p.Arg248Gln", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577538, "dbsnp_ids": ["11540652"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["Cytarabine"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Experiments were done in  MOLM-13 cell line (that the authors claim as being an AML cell line) expressing R273H mutation.", "support": "Moderate", "comment": null, "references": "PMID:31395785", "annotations": [], "created_on": "2020-05-22T14:36:17.603Z", "last_modified": "2020-05-22T14:36:17.604Z", "status": "draft", "request_id": null, "disease": {"name": "Acute myeloid leukemia, disease", "localization": "LEUKEMIA", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R273H", "hgvs_c": "NM_000546.5:c.818G>A", "hgvs_p": "NP_000537.3:p.Arg273His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577120, "dbsnp_ids": ["28934576"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["etoposide"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Experiments were done in  MOLM-13 cell line (that the authors claim as being an AML cell line) expressing R273H mutation.", "support": "Moderate", "comment": null, "references": "PMID:31395785", "annotations": [], "created_on": "2020-05-22T14:38:40.298Z", "last_modified": "2020-05-22T14:38:40.298Z", "status": "draft", "request_id": null, "disease": {"name": "Acute myeloid leukemia, disease", "localization": "LEUKEMIA", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R273H", "hgvs_c": "NM_000546.5:c.818G>A", "hgvs_p": "NP_000537.3:p.Arg273His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577120, "dbsnp_ids": ["28934576"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["Paclitaxel"], "interactions": [], "effect": "Sensitive (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Liver cancer cells Hep3B transfected with variant R273C are sensitive to paclitaxel.", "support": "Moderate", "comment": null, "references": "PMID:15004724", "annotations": [], "created_on": "2020-06-12T16:36:50.022Z", "last_modified": "2020-06-19T16:16:19.529Z", "status": "draft", "request_id": null, "disease": {"name": "Neoplasm of liver", "localization": "LIVER", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R273C", "hgvs_c": "NM_000546.5:c.817C>T", "hgvs_p": "NP_000537.3:p.Arg273Cys", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577121, "dbsnp_ids": ["121913343"]}, "extra_variants": []}, {"type_of_evidence": "Prognostic", "drugs": [], "interactions": [], "effect": "Poor outcome", "tier_level_criteria": "Population study", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Breast cancer patients who harbor R273H mutation have worse overall survival than those with wild type TP53, but have better prognosis than those with R248W mutation.", "support": "Moderate", "comment": null, "references": "PMID:16489069", "annotations": [], "created_on": "2020-05-26T17:40:58.892Z", "last_modified": "2020-05-27T09:35:42.278Z", "status": "draft", "request_id": null, "disease": {"name": "Carcinoma of breast", "localization": "BREAST", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R273H", "hgvs_c": "NM_000546.5:c.818G>A", "hgvs_p": "NP_000537.3:p.Arg273His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577120, "dbsnp_ids": ["28934576"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["AMGMDS3"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Assays performed in the pharyngeal carcinoma cell line Detroit562, that  expresses variant R175H, show that the MDM2 inhibitor AMGMDS3 doesn't have any effect on cell proliferation.", "support": "Moderate", "comment": null, "references": "PMID:25730903", "annotations": [], "created_on": "2020-05-28T12:41:34.295Z", "last_modified": "2020-05-28T13:33:59.995Z", "status": "draft", "request_id": null, "disease": {"name": "Head and neck squamous cell carcinoma", "localization": "HEAD AND NECK", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R175H", "hgvs_c": "NM_000546.5:c.524G>A", "hgvs_p": "NP_000537.3:p.Arg175His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7578406, "dbsnp_ids": ["28934578"]}, "extra_variants": []}, {"type_of_evidence": "Function", "drugs": [], "interactions": [], "effect": "Neomorphic", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "In breast cancer cell line HCC70, R248Q variant was shown to up-regulate chromatin regulatory genes, including methyltransferases KMT2A/MLL1, KMT2D/MLL2, and acetyltransferase KAT6A/MOZ, resulting in a genome-wide increase of histone methylation and acetylation, that may provide cancer cells with a selective growth advantage. This neomorphic function is dependent upon EST2-binding.", "support": "Strong", "comment": null, "references": "PMID:26331536", "annotations": [], "created_on": "2020-05-25T09:28:58.746Z", "last_modified": "2020-05-25T09:54:56.098Z", "status": "draft", "request_id": null, "disease": {"name": "Carcinoma of breast", "localization": "BREAST", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R248Q", "hgvs_c": "NM_000546.5:c.743G>A", "hgvs_p": "NP_000537.3:p.Arg248Gln", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577538, "dbsnp_ids": ["11540652"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["Doxorubicin"], "interactions": [], "effect": "Sensitive (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Liver cancer cells Hep3B transfected with variant R273C are sensitive to doxorubicin.", "support": "Moderate", "comment": null, "references": "PMID:15004724", "annotations": [], "created_on": "2020-06-12T16:00:17.800Z", "last_modified": "2020-06-19T16:16:22.950Z", "status": "draft", "request_id": null, "disease": {"name": "Neoplasm of liver", "localization": "LIVER", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R273C", "hgvs_c": "NM_000546.5:c.817C>T", "hgvs_p": "NP_000537.3:p.Arg273Cys", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577121, "dbsnp_ids": ["121913343"]}, "extra_variants": []}, {"type_of_evidence": "Function", "drugs": [], "interactions": [], "effect": "Loss of function", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "R175H variant exhibits nearly all DNA-binding activity. Acute myeloid leukemia cell lines K562 and MOLM13, expressing this  mutation, are resistant to DNA damage-induced apoptosis and failed to arrest in G1 following daunorubicin treatment.", "support": "Strong", "comment": null, "references": "PMID:31395785", "annotations": [], "created_on": "2020-05-20T15:36:54.042Z", "last_modified": "2020-05-22T13:59:56.122Z", "status": "draft", "request_id": null, "disease": {"name": "Acute myeloid leukemia, disease", "localization": "LEUKEMIA", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R175H", "hgvs_c": "NM_000546.5:c.524G>A", "hgvs_p": "NP_000537.3:p.Arg175His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7578406, "dbsnp_ids": ["28934578"]}, "extra_variants": []}, {"type_of_evidence": "Function", "drugs": [], "interactions": [], "effect": "Dominant negative", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "R248Q TP53 variant can form mixed tetramers with the wild-type protein, hence affecting the overall TP53 DNA-binding ability and acting as a dominant-negative mutation. In acute myeloid leukemia cell lines K562 and MOLM13 expressing R248Q variant, the strong dominant negative effect exerted by the mutation was measured at the transcriptional level.  In addition, cells heterozygous for the missense mutation and TP53-null cells were equally resistant to daunorubicin-induced apoptosis.", "support": "Strong", "comment": null, "references": "PMID:31395785", "annotations": [], "created_on": "2020-05-22T13:19:32.179Z", "last_modified": "2020-05-22T14:09:13.537Z", "status": "draft", "request_id": null, "disease": {"name": "Acute myeloid leukemia, disease", "localization": "LEUKEMIA", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R248Q", "hgvs_c": "NM_000546.5:c.743G>A", "hgvs_p": "NP_000537.3:p.Arg248Gln", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577538, "dbsnp_ids": ["11540652"]}, "extra_variants": []}, {"type_of_evidence": "Function", "drugs": [], "interactions": [], "effect": "Loss of function", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "R248Q variant exhibits nearly all DNA-binding activity. Acute myeloid leukemia cell lines K562 and MOLM13, expressing this  variant, are resistant to DNA damage-induced apoptosis and failed to arrest in G1 following daunorubicin treatment.", "support": "Strong", "comment": null, "references": "PMID:31395785", "annotations": [], "created_on": "2020-05-22T09:41:06.211Z", "last_modified": "2020-05-22T14:09:24.690Z", "status": "draft", "request_id": null, "disease": {"name": "Acute myeloid leukemia, disease", "localization": "LEUKEMIA", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R248Q", "hgvs_c": "NM_000546.5:c.743G>A", "hgvs_p": "NP_000537.3:p.Arg248Gln", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577538, "dbsnp_ids": ["11540652"]}, "extra_variants": []}, {"type_of_evidence": "Function", "drugs": [], "interactions": [], "effect": "Dominant negative", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "R175H TP53 variant can form mixed tetramers with the wild-type protein, hence affecting the overall TP53 DNA-binding ability and acting as a dominant-negative mutation. In acute myeloid leukemia cell lines K562 and MOLM13, that were edited by CRISPR-CAS9 to introduce R175H variant, the strong dominant negative effect exerted by the R175H  mutation was measured at the transcriptional level.  In addition, cells heterozygous for the missense mutation and TP53-null cells were equally resistant to daunorubicin-induced apoptosis.", "support": "Strong", "comment": "", "references": "PMID:31395785", "annotations": [], "created_on": "2020-05-19T15:00:05.182Z", "last_modified": "2020-05-22T13:02:21.209Z", "status": "draft", "request_id": null, "disease": {"name": "Acute myeloid leukemia, disease", "localization": "LEUKEMIA", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R175H", "hgvs_c": "NM_000546.5:c.524G>A", "hgvs_p": "NP_000537.3:p.Arg175His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7578406, "dbsnp_ids": ["28934578"]}, "extra_variants": []}, {"type_of_evidence": "Function", "drugs": [], "interactions": [], "effect": "Neomorphic", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "In breast cancer cell line MDA-MB-468, R273H variant was shown to up-regulate chromatin regulatory genes, including methyltransferases KMT2A/MLL1, KMT2D/MLL2, and acetyltransferase KAT6A/MOZ, resulting in a genome-wide increase of histone methylation and acetylation, that may provide cancer cells with a selective growth advantage. This neomorphic function is dependent upon EST2-binding.", "support": "Strong", "comment": null, "references": "PMID:26331536", "annotations": [], "created_on": "2020-05-25T09:18:25.242Z", "last_modified": "2020-06-19T14:43:42.480Z", "status": "draft", "request_id": null, "disease": {"name": "Carcinoma of breast", "localization": "BREAST", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R273H", "hgvs_c": "NM_000546.5:c.818G>A", "hgvs_p": "NP_000537.3:p.Arg273His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577120, "dbsnp_ids": ["28934576"]}, "extra_variants": []}, {"type_of_evidence": "Function", "drugs": [], "interactions": [], "effect": "Loss of function", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "R273H variant exhibits nearly all DNA-binding activity. Acute myeloid leukemia cell lines K562 and MOLM13, expressing this  variant, are resistant to DNA damage-induced apoptosis and failed to arrest in G1 following daunorubicin treatment.", "support": "Strong", "comment": null, "references": "PMID:31395785", "annotations": [], "created_on": "2020-05-22T09:41:00.776Z", "last_modified": "2020-05-22T14:10:14.297Z", "status": "draft", "request_id": null, "disease": {"name": "Acute myeloid leukemia, disease", "localization": "LEUKEMIA", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R273H", "hgvs_c": "NM_000546.5:c.818G>A", "hgvs_p": "NP_000537.3:p.Arg273His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577120, "dbsnp_ids": ["28934576"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["daunorubicin"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Experiments were done in  MOLM-13 cell line (that the authors claim as being an AML cell line) expressing R248Q mutation.", "support": "Moderate", "comment": null, "references": "PMID:31395785", "annotations": [], "created_on": "2020-05-22T14:29:28.548Z", "last_modified": "2020-05-22T14:29:28.548Z", "status": "draft", "request_id": null, "disease": {"name": "Acute myeloid leukemia, disease", "localization": "LEUKEMIA", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R248Q", "hgvs_c": "NM_000546.5:c.743G>A", "hgvs_p": "NP_000537.3:p.Arg248Gln", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577538, "dbsnp_ids": ["11540652"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["nutlin-3a"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Experiments were done in  MOLM-13 cell line (that the authors claim as being an AML cell line) expressing R273H mutation.", "support": "Moderate", "comment": null, "references": "PMID:31395785", "annotations": [], "created_on": "2020-05-22T14:34:20.417Z", "last_modified": "2020-05-22T14:34:20.417Z", "status": "draft", "request_id": null, "disease": {"name": "Acute myeloid leukemia, disease", "localization": "LEUKEMIA", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R273H", "hgvs_c": "NM_000546.5:c.818G>A", "hgvs_p": "NP_000537.3:p.Arg273His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577120, "dbsnp_ids": ["28934576"]}, "extra_variants": []}, {"type_of_evidence": "Prognostic", "drugs": [], "interactions": [], "effect": "Poor outcome", "tier_level_criteria": "Population study", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Both the relapse-free and overall survival of patients with TP53 mutations in either the conserved regions, within L2 and L3 (including R248Q), or the codons that directly contact DNA, including R248Q, is significantly worse than those patients without mutations, or with mutations in codons that are not conserved or are outside L2 and L3. The main caveat of this study is the low number of patients (only 66 tumor samples were sequenced).", "support": "Low", "comment": null, "references": "PMID:9569050", "annotations": [], "created_on": "2020-05-27T09:28:45.618Z", "last_modified": "2020-05-27T09:33:31.723Z", "status": "draft", "request_id": null, "disease": {"name": "Carcinoma of breast", "localization": "BREAST", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R248Q", "hgvs_c": "NM_000546.5:c.743G>A", "hgvs_p": "NP_000537.3:p.Arg248Gln", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577538, "dbsnp_ids": ["11540652"]}, "extra_variants": []}, {"type_of_evidence": "Prognostic", "drugs": [], "interactions": [], "effect": "Poor outcome", "tier_level_criteria": "Population study", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Both the relapse-free and overall survival of patients with TP53 mutations in either the conserved regions, within L2 and L3, or the codons that directly contact DNA, including R273H, is significantly worse than those patients without mutations, or with mutations in codons that are not conserved or are outside L2 and L3. The main caveat of this study is the low number of patients (only 66 tumor samples were sequenced).", "support": "Low", "comment": null, "references": "PMID:9569050", "annotations": [], "created_on": "2020-05-27T08:29:03.721Z", "last_modified": "2020-05-27T09:33:50.510Z", "status": "draft", "request_id": null, "disease": {"name": "Carcinoma of breast", "localization": "BREAST", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R273H", "hgvs_c": "NM_000546.5:c.818G>A", "hgvs_p": "NP_000537.3:p.Arg273His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577120, "dbsnp_ids": ["28934576"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["Doxorubicin"], "interactions": [], "effect": "Responsive", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "When breast tumors were tested in a mouse model, tumors homozygous for p.Arg172His (homologous to human p.Arg175His), had significantly greater decrease in tumor volume and significantly longer time to relapse compared to tumors expressing wild-type TP53 in response to doxorubicin treatment, although tumors of all genotypes eventually relapsed. The mutant mouse cells did not exit cell cycle in response to doxorubicin treatment, resulting in aberrant mitoses and increased apoptosis.", "support": "Low", "comment": null, "references": "PMID:22698404", "annotations": [], "created_on": "2020-05-28T08:42:19.679Z", "last_modified": "2020-05-28T09:08:23.173Z", "status": "draft", "request_id": null, "disease": {"name": "Carcinoma of breast", "localization": "BREAST", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R175H", "hgvs_c": "NM_000546.5:c.524G>A", "hgvs_p": "NP_000537.3:p.Arg175His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7578406, "dbsnp_ids": ["28934578"]}, "extra_variants": []}, {"type_of_evidence": "Interaction", "drugs": [], "interactions": ["NFE2L2"], "effect": "New interaction partner(s)", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "In MDA-MB-468 cell line and other cell lines, variant R273H, but not wild-type TP53, interacts with NFE2L2 (also called NRF2).", "support": "Strong", "comment": "", "references": "PMID:27347849", "annotations": [], "created_on": "2020-05-26T13:06:02.029Z", "last_modified": "2020-05-26T14:27:56.382Z", "status": "draft", "request_id": null, "disease": {"name": "Carcinoma of breast", "localization": "BREAST", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R273H", "hgvs_c": "NM_000546.5:c.818G>A", "hgvs_p": "NP_000537.3:p.Arg273His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577120, "dbsnp_ids": ["28934576"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["AMGMDS3"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Assays performed in the rectal adenocarcinoma cell line SW837, that  expresses variant R248W, show that the MDM2 inhibitor AMGMDS3 doesn't have any effect on cell proliferation.", "support": "Moderate", "comment": null, "references": "PMID:25730903", "annotations": [], "created_on": "2020-05-28T14:11:16.768Z", "last_modified": "2020-05-28T14:11:27.067Z", "status": "draft", "request_id": null, "disease": {"name": "Adenocarcinoma of colorectum", "localization": "RECTUM", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R248W", "hgvs_c": "NM_000546.5:c.742C>T", "hgvs_p": "NP_000537.3:p.Arg248Trp", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577539, "dbsnp_ids": ["121912651"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["AMGMDS3"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Assays performed in the pancreas carcinoma cell line MIA-PaCa-2, that  expresses variant R248W, show that the MDM2 inhibitor AMGMDS3 doesn't have any effect on cell proliferation.", "support": "Moderate", "comment": null, "references": "PMID:25730903", "annotations": [], "created_on": "2020-05-28T14:02:19.330Z", "last_modified": "2020-05-28T14:11:37.306Z", "status": "draft", "request_id": null, "disease": {"name": "Adenocarcinoma of pancreas", "localization": "PANCREAS", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R248W", "hgvs_c": "NM_000546.5:c.742C>T", "hgvs_p": "NP_000537.3:p.Arg248Trp", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577539, "dbsnp_ids": ["121912651"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["AMGMDS3"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Assays performed in the colorectal adenocarcinoma cell line SW1463, that  expresses variant R248Q, show that the MDM2 inhibitor AMGMDS3 doesn't have any effect on cell proliferation.", "support": "Moderate", "comment": "", "references": "PMID:25730903", "annotations": [], "created_on": "2020-05-28T14:52:22.640Z", "last_modified": "2020-05-28T14:52:22.640Z", "status": "draft", "request_id": null, "disease": {"name": "Adenocarcinoma of colorectum", "localization": "COLORECTUM", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R248Q", "hgvs_c": "NM_000546.5:c.743G>A", "hgvs_p": "NP_000537.3:p.Arg248Gln", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577538, "dbsnp_ids": ["11540652"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["AMGMDS3"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Assays performed in the ovarian adenocarcinoma cell line OVCAR-3, that  expresses variant R248Q, show that the MDM2 inhibitor AMGMDS3 doesn't have any effect on cell proliferation.", "support": "Moderate", "comment": null, "references": "PMID:25730903", "annotations": [], "created_on": "2020-05-28T14:30:03.843Z", "last_modified": "2020-05-28T14:52:28.061Z", "status": "draft", "request_id": null, "disease": {"name": "Neoplasm of ovary", "localization": "OVARY", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R248Q", "hgvs_c": "NM_000546.5:c.743G>A", "hgvs_p": "NP_000537.3:p.Arg248Gln", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577538, "dbsnp_ids": ["11540652"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["AMGMDS3"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Assays performed in the stomach carcinoma cell line NCI-N87, that  expresses variant R248Q, show that the MDM2 inhibitor AMGMDS3 doesn't have any effect on cell proliferation.", "support": "Moderate", "comment": null, "references": "PMID:25730903", "annotations": [], "created_on": "2020-05-28T14:26:41.906Z", "last_modified": "2020-05-28T14:52:33.418Z", "status": "draft", "request_id": null, "disease": {"name": "Adenocarcinoma of stomach", "localization": "STOMACH", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R248Q", "hgvs_c": "NM_000546.5:c.743G>A", "hgvs_p": "NP_000537.3:p.Arg248Gln", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577538, "dbsnp_ids": ["11540652"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["AMGMDS3"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Assays performed in the bile duct carcinoma cell line HuCCT1, that  expresses variant R175H, show that the MDM2 inhibitor AMGMDS3 doesn't have any effect on cell proliferation.", "support": "Moderate", "comment": null, "references": "PMID:25730903", "annotations": [], "created_on": "2020-05-28T13:48:09.497Z", "last_modified": "2020-09-23T13:48:18.895Z", "status": "draft", "request_id": null, "disease": {"name": "Bile Duct Carcinoma", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R175H", "hgvs_c": "NM_000546.5:c.524G>A", "hgvs_p": "NP_000537.3:p.Arg175His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7578406, "dbsnp_ids": ["28934578"]}, "extra_variants": []}, {"type_of_evidence": "Prognostic", "drugs": [], "interactions": [], "effect": "Poor outcome", "tier_level_criteria": "Population study", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Both the relapse-free and overall survival of patients with TP53 mutations in either the conserved regions, within L2 (including R175H) and L3, or the codons that directly contact DNA is significantly worse than those patients without mutations, or with mutations in codons that are not conserved or are outside L2 and L3. The main caveat of this study is the low number of patients (only 66 tumor samples were sequenced).", "support": "Low", "comment": null, "references": "PMID:9569050", "annotations": [], "created_on": "2020-05-27T09:33:07.807Z", "last_modified": "2020-05-27T09:33:07.807Z", "status": "draft", "request_id": null, "disease": {"name": "Carcinoma of breast", "localization": "BREAST", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R175H", "hgvs_c": "NM_000546.5:c.524G>A", "hgvs_p": "NP_000537.3:p.Arg175His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7578406, "dbsnp_ids": ["28934578"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["Carfilzomib"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Resistance to carfilzomib  alone was tested in breast cancer MDA-MB-468 cell line.", "support": "Low", "comment": null, "references": "PMID:27347849", "annotations": [], "created_on": "2020-05-26T14:04:59.626Z", "last_modified": "2020-05-26T14:27:52.527Z", "status": "draft", "request_id": null, "disease": {"name": "Carcinoma of breast", "localization": "BREAST", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R273H", "hgvs_c": "NM_000546.5:c.818G>A", "hgvs_p": "NP_000537.3:p.Arg273His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577120, "dbsnp_ids": ["28934576"]}, "extra_variants": []}, {"type_of_evidence": "Function", "drugs": [], "interactions": [], "effect": "Neomorphic", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "In breast cancer cell line MDA-MB-468, variant R273H, through its association with NRF2/NFE2L2,  increases proteasome gene transcription.", "support": "Strong", "comment": null, "references": "PMID:27347849", "annotations": [], "created_on": "2020-05-26T13:03:14.443Z", "last_modified": "2020-05-26T14:28:00.420Z", "status": "draft", "request_id": null, "disease": {"name": "Carcinoma of breast", "localization": "BREAST", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R273H", "hgvs_c": "NM_000546.5:c.818G>A", "hgvs_p": "NP_000537.3:p.Arg273His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577120, "dbsnp_ids": ["28934576"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["Carfilzomib", "PRIMA-1Met"], "interactions": [], "effect": "Sensitive (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Sensitivity to drugs was tested in the triple-negative  breast cancer cell line HCC-1395.", "support": "Low", "comment": null, "references": "PMID:27347849", "annotations": [], "created_on": "2020-05-19T17:48:14.411Z", "last_modified": "2020-05-26T14:28:03.999Z", "status": "draft", "request_id": null, "disease": {"name": "Carcinoma of breast", "localization": "BREAST", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R175H", "hgvs_c": "NM_000546.5:c.524G>A", "hgvs_p": "NP_000537.3:p.Arg175His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7578406, "dbsnp_ids": ["28934578"]}, "extra_variants": []}, {"type_of_evidence": "Prognostic", "drugs": [], "interactions": [], "effect": "Poor outcome", "tier_level_criteria": "Population study", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Both the relapse-free and overall survival of patients with TP53 mutations in either the conserved regions, within L2 and L3 (including R248W), or the codons that directly contact DNA, including R248W, is significantly worse than those patients without mutations, or with mutations in codons that are not conserved or are outside L2 and L3. The main caveat of this study is the low number of patients (only 66 tumor samples were sequenced).", "support": "Low", "comment": null, "references": "PMID:9569050", "annotations": [], "created_on": "2020-05-27T09:27:55.958Z", "last_modified": "2020-05-27T09:33:39.332Z", "status": "draft", "request_id": null, "disease": {"name": "Carcinoma of breast", "localization": "BREAST", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R248W", "hgvs_c": "NM_000546.5:c.742C>T", "hgvs_p": "NP_000537.3:p.Arg248Trp", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577539, "dbsnp_ids": ["121912651"]}, "extra_variants": []}, {"type_of_evidence": "Prognostic", "drugs": [], "interactions": [], "effect": "Poor outcome", "tier_level_criteria": "Population study", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Breast cancer patients who harbor R248Q mutation have worse overall survival than those with wild type TP53, but have better prognosis than those with R248W mutation.", "support": "Moderate", "comment": null, "references": "PMID:16489069", "annotations": [], "created_on": "2020-05-26T17:44:41.023Z", "last_modified": "2020-05-27T09:35:10.645Z", "status": "draft", "request_id": null, "disease": {"name": "Carcinoma of breast", "localization": "BREAST", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R248Q", "hgvs_c": "NM_000546.5:c.743G>A", "hgvs_p": "NP_000537.3:p.Arg248Gln", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577538, "dbsnp_ids": ["11540652"]}, "extra_variants": []}, {"type_of_evidence": "Prognostic", "drugs": [], "interactions": [], "effect": "Poor outcome", "tier_level_criteria": "Population study", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Breast cancer patients who harbor R248W mutation have a much worse overall survival than those with wild type TP53, and worse than other missense mutations within TP53 DNA-binding domain.", "support": "Moderate", "comment": null, "references": "PMID:16489069", "annotations": [], "created_on": "2020-05-26T17:28:27.371Z", "last_modified": "2020-05-27T09:36:00.888Z", "status": "draft", "request_id": null, "disease": {"name": "Carcinoma of breast", "localization": "BREAST", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R248W", "hgvs_c": "NM_000546.5:c.742C>T", "hgvs_p": "NP_000537.3:p.Arg248Trp", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577539, "dbsnp_ids": ["121912651"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["Carfilzomib", "Vorinostat"], "interactions": [], "effect": "Sensitive (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Combining vorinostat (also called SAHA) with the proteasome inhibitor carfilzomib is effective in overcoming chemoresistance in the triple-negative breast cancer  MDA-MB-468 cell line.", "support": "Low", "comment": null, "references": "PMID:27347849", "annotations": [], "created_on": "2020-05-26T14:26:02.476Z", "last_modified": "2020-06-17T18:45:51.193Z", "status": "draft", "request_id": null, "disease": {"name": "Carcinoma of breast", "localization": "BREAST", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R273H", "hgvs_c": "NM_000546.5:c.818G>A", "hgvs_p": "NP_000537.3:p.Arg273His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577120, "dbsnp_ids": ["28934576"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["AMGMDS3"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Assays performed in the breast cancer cell line AU565, that  expresses variant R175H, show that the MDM2 inhibitor AMGMDS3 doesn't have any effect on cell proliferation.", "support": "Moderate", "comment": "", "references": "PMID:25730903", "annotations": [], "created_on": "2020-05-28T12:37:35.833Z", "last_modified": "2020-05-28T13:34:02.627Z", "status": "draft", "request_id": null, "disease": {"name": "Carcinoma of breast", "localization": "BREAST", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R175H", "hgvs_c": "NM_000546.5:c.524G>A", "hgvs_p": "NP_000537.3:p.Arg175His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7578406, "dbsnp_ids": ["28934578"]}, "extra_variants": []}, {"type_of_evidence": "Function", "drugs": [], "interactions": [], "effect": "Neomorphic", "tier_level_criteria": null, "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Variant R273H is required for the up-regulation of cell cycle gene expression, including that of cyclin-A (CCNA2), cyclin-B1 (CCNB1), cyclin-B2 (CCNB2), CDC25C and CDK1, in response to DNA-damaging agent adriamycin in colon adenocarcinoma cell line HT29, leading to increase in DNA synthesis.", "support": "Moderate", "comment": null, "references": "PMID:16959611", "annotations": [], "created_on": "2020-05-26T15:43:45.710Z", "last_modified": "2020-06-19T13:29:32.963Z", "status": "draft", "request_id": null, "disease": {"name": "Adenocarcinoma of colorectum", "localization": "COLON", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R273H", "hgvs_c": "NM_000546.5:c.818G>A", "hgvs_p": "NP_000537.3:p.Arg273His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577120, "dbsnp_ids": ["28934576"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["AMGMDS3"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Assays performed in the colon adenocarcinoma cell line COLO-320-HSR, that  expresses variant R248W, show that the MDM2 inhibitor AMGMDS3 doesn't have any effect on cell proliferation.", "support": "Moderate", "comment": null, "references": "PMID:25730903", "annotations": [], "created_on": "2020-05-28T14:00:15.215Z", "last_modified": "2020-05-28T14:11:42.460Z", "status": "draft", "request_id": null, "disease": {"name": "Adenocarcinoma of colorectum", "localization": "COLON", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R248W", "hgvs_c": "NM_000546.5:c.742C>T", "hgvs_p": "NP_000537.3:p.Arg248Trp", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577539, "dbsnp_ids": ["121912651"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["Doxorubicin"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "SKBR3 cells expressing  TP53 R175H variant show reduced cell death following doxorubicin (also known as adriamycin) treatment, compared to cells in which the variant has been knocked down.", "support": "Moderate", "comment": null, "references": "PMID:16959611", "annotations": [], "created_on": "2020-05-26T17:04:26.222Z", "last_modified": "2020-05-26T17:07:36.864Z", "status": "draft", "request_id": null, "disease": {"name": "Carcinoma of breast", "localization": "BREAST", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R175H", "hgvs_c": "NM_000546.5:c.524G>A", "hgvs_p": "NP_000537.3:p.Arg175His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7578406, "dbsnp_ids": ["28934578"]}, "extra_variants": []}, {"type_of_evidence": "Function", "drugs": [], "interactions": [], "effect": "Neomorphic", "tier_level_criteria": null, "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Variant R175H is required for the up-regulation of cell cycle gene expression, including that of cyclin-A (CCNA2), cyclin-B1 (CCNB1), cyclin-B2 (CCNB2), CDC25C and CDK1, in response to DNA-damaging agent adriamycin in colon adenocarcinoma cell line SKBR3, leading to increase in DNA synthesis.", "support": "Moderate", "comment": null, "references": "PMID:16959611", "annotations": [], "created_on": "2020-05-26T15:40:16.914Z", "last_modified": "2020-05-26T17:07:45.330Z", "status": "draft", "request_id": null, "disease": {"name": "Carcinoma of breast", "localization": "BREAST", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R175H", "hgvs_c": "NM_000546.5:c.524G>A", "hgvs_p": "NP_000537.3:p.Arg175His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7578406, "dbsnp_ids": ["28934578"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["AMGMDS3"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Assays performed in the endometrium adenocarcinoma cell line KLE, that  expresses variant R175H, show that the MDM2 inhibitor AMGMDS3 doesn't have any effect on cell proliferation.", "support": "Moderate", "comment": null, "references": "PMID:25730903", "annotations": [], "created_on": "2020-05-28T13:50:41.882Z", "last_modified": "2020-05-29T12:09:57.617Z", "status": "draft", "request_id": null, "disease": {"name": "Neoplasm of endometrium", "localization": "ENDOMETRIUM", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R175H", "hgvs_c": "NM_000546.5:c.524G>A", "hgvs_p": "NP_000537.3:p.Arg175His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7578406, "dbsnp_ids": ["28934578"]}, "extra_variants": []}, {"type_of_evidence": "Prognostic", "drugs": [], "interactions": [], "effect": "Poor outcome", "tier_level_criteria": "Population study", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Both the relapse-free and overall survival of patients with TP53 mutations in either the conserved regions, within L2 and L3 (including G245S), or the codons that directly contact DNA is significantly worse than those patients without mutations, or with mutations in codons that are not conserved or are outside L2 and L3. The main caveat of this study is the low number of patients (only 66 tumor samples were sequenced).", "support": "Low", "comment": null, "references": "PMID:9569050", "annotations": [], "created_on": "2020-05-27T09:31:29.696Z", "last_modified": "2020-06-22T08:13:14.791Z", "status": "draft", "request_id": null, "disease": {"name": "Carcinoma of breast", "localization": "BREAST", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "G245S", "hgvs_c": "NM_000546.5:c.733G>A", "hgvs_p": "NP_000537.3:p.Gly245Ser", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577548, "dbsnp_ids": ["28934575"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["AMGMDS3"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Assays performed in the small cell lung carcinoma cell line DMS-114, that  expresses variant R213ter, show that the MDM2 inhibitor AMGMDS3 doesn't have any effect on cell proliferation.", "support": "Moderate", "comment": null, "references": "PMID:25730903", "annotations": [], "created_on": "2020-05-28T15:07:35.699Z", "last_modified": "2020-05-28T15:07:45.730Z", "status": "draft", "request_id": null, "disease": {"name": "Small cell carcinoma of lung", "localization": "LUNG", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R213*", "hgvs_c": "ENST00000269305:c.637C>T", "hgvs_p": null, "reference_name": "GrCh37", "chromosome": "chr17", "start_pos": 7578212, "dbsnp_ids": null}, "extra_variants": []}, {"type_of_evidence": "Variant identification", "drugs": [], "interactions": [], "effect": null, "tier_level_criteria": null, "tier_level": null, "mutation_origin": "Germline", "associated_mendelian_diseases": "Li-Fraumeni syndrome", "summary": null, "support": "Strong", "comment": null, "references": "PMID:1565144", "annotations": [], "created_on": "2020-06-19T14:37:34.495Z", "last_modified": "2020-09-23T13:48:18.938Z", "status": "draft", "request_id": null, "disease": null, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R273H", "hgvs_c": "NM_000546.5:c.818G>A", "hgvs_p": "NP_000537.3:p.Arg273His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577120, "dbsnp_ids": ["28934576"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["AMGMDS3"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Assays performed in the astrocytoma cell line SW1088, that  expresses variant R273C, show that the MDM2 inhibitor AMGMDS3 doesn't have any effect on cell proliferation.", "support": "Moderate", "comment": "REPLACE DISEASE BY:", "references": "PMID:25730903", "annotations": [], "created_on": "2020-05-28T15:17:28.337Z", "last_modified": "2020-05-28T15:17:43.753Z", "status": "draft", "request_id": null, "disease": {"name": "Neoplasm of brain", "localization": "BRAIN", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R273C", "hgvs_c": "NM_000546.5:c.817C>T", "hgvs_p": "NP_000537.3:p.Arg273Cys", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577121, "dbsnp_ids": ["121913343"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["Doxorubicin"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "The liver cancer cells Hep3B transfected with variant R248Q are resistant to doxorubicin compared to untransfected TP53-null cells or R273C transfected cells. The resistance may be possibly mediated through the upregulation of multiple resistance protein ABCB1/P-glycoprotein, which reduces the accumulation of doxorubicin within treated cells.", "support": "Moderate", "comment": null, "references": "PMID:15004724", "annotations": [], "created_on": "2020-06-11T16:05:57.120Z", "last_modified": "2020-06-12T16:44:07.398Z", "status": "draft", "request_id": null, "disease": {"name": "Neoplasm of liver", "localization": "LIVER", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R248Q", "hgvs_c": "NM_000546.5:c.743G>A", "hgvs_p": "NP_000537.3:p.Arg248Gln", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577538, "dbsnp_ids": ["11540652"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["AMGMDS3"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Assays performed in the endometrium adenocarcinoma cell line HEC-1-A, that expresses variant R248Q, show that the MDM2 inhibitor AMGMDS3 doesn't have any effect on cell proliferation.", "support": "Moderate", "comment": null, "references": "PMID:25730903", "annotations": [], "created_on": "2020-05-28T14:23:29.426Z", "last_modified": "2020-06-12T17:24:33.656Z", "status": "draft", "request_id": null, "disease": {"name": "Neoplasm of endometrium", "localization": "ENDOMETRIUM", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R248Q", "hgvs_c": "NM_000546.5:c.743G>A", "hgvs_p": "NP_000537.3:p.Arg248Gln", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577538, "dbsnp_ids": ["11540652"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["AMGMDS3"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Assays performed in the astrocytoma cell line SNB-19, that  expresses variant R273H, show that the MDM2 inhibitor AMGMDS3 doesn't have any effect on cell proliferation.", "support": "Moderate", "comment": "REPLACE BY: astrocytoma", "references": "PMID:25730903", "annotations": [], "created_on": "2020-05-28T15:33:24.306Z", "last_modified": "2020-05-28T15:36:36.394Z", "status": "draft", "request_id": null, "disease": {"name": "Neoplasm of brain", "localization": "BRAIN", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R273H", "hgvs_c": "NM_000546.5:c.818G>A", "hgvs_p": "NP_000537.3:p.Arg273His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577120, "dbsnp_ids": ["28934576"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["AMGMDS3"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Assays performed in the pancreatic carcinoma cell line PANC-1, that  expresses variant R273H, show that the MDM2 inhibitor AMGMDS3 doesn't have any effect on cell proliferation.", "support": "Moderate", "comment": null, "references": "PMID:25730903", "annotations": [], "created_on": "2020-05-28T15:31:19.272Z", "last_modified": "2020-05-28T15:36:44.619Z", "status": "draft", "request_id": null, "disease": {"name": "Adenocarcinoma of pancreas", "localization": "PANCREAS", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R273H", "hgvs_c": "NM_000546.5:c.818G>A", "hgvs_p": "NP_000537.3:p.Arg273His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577120, "dbsnp_ids": ["28934576"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["AMGMDS3"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Assays performed in the colorectal adenocarcinoma cell lines NCI-H508 and WiDr, that  express variant R273H, show that the MDM2 inhibitor AMGMDS3 doesn't have any effect on cell proliferation.", "support": "Moderate", "comment": "", "references": "PMID:25730903", "annotations": [], "created_on": "2020-05-28T15:29:43.996Z", "last_modified": "2020-05-28T15:36:49.440Z", "status": "draft", "request_id": null, "disease": {"name": "Adenocarcinoma of colorectum", "localization": "RECTUM", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R273H", "hgvs_c": "NM_000546.5:c.818G>A", "hgvs_p": "NP_000537.3:p.Arg273His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577120, "dbsnp_ids": ["28934576"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["Carfilzomib", "PRIMA-1Met"], "interactions": [], "effect": "Sensitive (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Combining the mutant p53-inactivating agentPRIMA-1MET with the proteasome inhibitor carfilzomib is effective in overcoming chemoresistance in triple-negative breast cancer cells.", "support": "Low", "comment": "Sensitivity to carfilzomib and PRIMA-1Met  was tested in breast cancer MDA-MB-468 cell line.", "references": "PMID:27347849", "annotations": [], "created_on": "2020-05-26T14:14:21.977Z", "last_modified": "2020-06-17T18:45:44.735Z", "status": "draft", "request_id": null, "disease": {"name": "Carcinoma of breast", "localization": "BREAST", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R273H", "hgvs_c": "NM_000546.5:c.818G>A", "hgvs_p": "NP_000537.3:p.Arg273His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577120, "dbsnp_ids": ["28934576"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": [], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Assays performed in the breast carcinoma cell line MDA-MB-468, that  expresses variant R273H, show that the MDM2 inhibitor AMGMDS3 doesn't have any effect on cell proliferation.", "support": "Moderate", "comment": null, "references": "PMID:25730903", "annotations": [], "created_on": "2020-05-28T15:28:08.400Z", "last_modified": "2020-05-28T15:36:55.122Z", "status": "draft", "request_id": null, "disease": {"name": "Carcinoma of breast", "localization": "BREAST", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R273H", "hgvs_c": "NM_000546.5:c.818G>A", "hgvs_p": "NP_000537.3:p.Arg273His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577120, "dbsnp_ids": ["28934576"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["AMGMDS3"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Assays performed in the colorectal carcinoma cell line LS-1034, that  expresses variant G245S, show that the MDM2 inhibitor AMGMDS3 doesn't have any effect on cell proliferation.", "support": "Moderate", "comment": null, "references": "PMID:25730903", "annotations": [], "created_on": "2020-05-28T15:39:27.092Z", "last_modified": "2020-06-22T08:13:20.326Z", "status": "draft", "request_id": null, "disease": {"name": "Adenocarcinoma of colorectum", "localization": "RECTUM", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "G245S", "hgvs_c": "NM_000546.5:c.733G>A", "hgvs_p": "NP_000537.3:p.Gly245Ser", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577548, "dbsnp_ids": ["28934575"]}, "extra_variants": []}, {"type_of_evidence": "Variant identification", "drugs": [], "interactions": [], "effect": null, "tier_level_criteria": null, "tier_level": null, "mutation_origin": "Germline", "associated_mendelian_diseases": "Li-Fraumeni syndrome", "summary": null, "support": "Strong", "comment": null, "references": "PMID:10797439", "annotations": [], "created_on": "2020-06-15T19:03:57.533Z", "last_modified": "2020-09-23T13:48:19.007Z", "status": "draft", "request_id": null, "disease": null, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R248Q", "hgvs_c": "NM_000546.5:c.743G>A", "hgvs_p": "NP_000537.3:p.Arg248Gln", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577538, "dbsnp_ids": ["11540652"]}, "extra_variants": []}, {"type_of_evidence": "Prognostic", "drugs": [], "interactions": [], "effect": "Poor outcome", "tier_level_criteria": "Population study", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Out of total number of 947 early-stage endometrioid endometrial carcinomas, Stelloo et al. identified a small subset bearing CTNNB1 mutations, including T41A in 11 tumors, which tended to exhibit  a more aggressive behavior.", "support": "Low", "comment": null, "references": "PMID:27006490", "annotations": [], "created_on": "2020-08-14T10:14:16.397Z", "last_modified": "2020-08-14T10:15:17.702Z", "status": "draft", "request_id": null, "disease": {"name": "Endometrioid adenocarcinoma", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "CTNNB1", "name": "T41A", "hgvs_c": "ENST00000349496:c.121A>G", "hgvs_p": null, "reference_name": "GrCh37", "chromosome": "chr3", "start_pos": 41266124, "dbsnp_ids": null}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["mitoxantrone"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Experiments were done in  MOLM-13 cell line (that the authors claim as being an AML cell line) expressing R273H mutation.", "support": "Moderate", "comment": null, "references": "PMID:31395785", "annotations": [], "created_on": "2020-05-22T14:37:45.840Z", "last_modified": "2020-06-17T18:57:54.598Z", "status": "draft", "request_id": null, "disease": {"name": "Acute myeloid leukemia, disease", "localization": "LEUKEMIA", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R273H", "hgvs_c": "NM_000546.5:c.818G>A", "hgvs_p": "NP_000537.3:p.Arg273His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577120, "dbsnp_ids": ["28934576"]}, "extra_variants": []}, {"type_of_evidence": "Interaction", "drugs": [], "interactions": ["NFYA", "EP300"], "effect": "New interaction partner(s)", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "As wild-type TP53, variant R175H interacts with the heterotrimeric NF-Y  transcription factor, composed of NFYA, NFYB and NFYC. However, upon DNA damage, such as that caused by adriamycin treatment, the complex NFYA-R175H selectively recruits EP300 acetylase, while wild-type TP53 tends to recruit deacetylase HDAC1, hence determining the activation or repression of target genes, respectively.", "support": "Moderate", "comment": null, "references": "PMID:16959611", "annotations": [], "created_on": "2020-05-26T16:58:32.225Z", "last_modified": "2020-06-19T13:28:27.086Z", "status": "draft", "request_id": null, "disease": {"name": "Carcinoma of breast", "localization": "BREAST", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R175H", "hgvs_c": "NM_000546.5:c.524G>A", "hgvs_p": "NP_000537.3:p.Arg175His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7578406, "dbsnp_ids": ["28934578"]}, "extra_variants": []}, {"type_of_evidence": "Interaction", "drugs": [], "interactions": ["NFYA", "NFYB"], "effect": "Other", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "As wild-type TP53, R273H interacts with  the heterotrimeric NF-Y  transcription factor, composed of NFYA, NFYB and NFYC.", "support": "Strong", "comment": null, "references": "PMID:16959611", "annotations": [], "created_on": "2020-06-19T11:24:44.293Z", "last_modified": "2020-06-19T13:28:44.535Z", "status": "draft", "request_id": null, "disease": {"name": "Adenocarcinoma of colorectum", "localization": "RECTUM", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R273H", "hgvs_c": "NM_000546.5:c.818G>A", "hgvs_p": "NP_000537.3:p.Arg273His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577120, "dbsnp_ids": ["28934576"]}, "extra_variants": []}, {"type_of_evidence": "Interaction", "drugs": [], "interactions": ["NFYA", "NFYB"], "effect": "Other", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "As wild-type TP53, R175H interacts with  the heterotrimeric NF-Y  transcription factor, composed of NFYA, NFYB and NFYC.", "support": "Strong", "comment": null, "references": "PMID:16959611", "annotations": [], "created_on": "2020-06-19T11:22:50.377Z", "last_modified": "2020-06-19T13:29:50.652Z", "status": "draft", "request_id": null, "disease": {"name": "Carcinoma of breast", "localization": "BREAST", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R175H", "hgvs_c": "NM_000546.5:c.524G>A", "hgvs_p": "NP_000537.3:p.Arg175His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7578406, "dbsnp_ids": ["28934578"]}, "extra_variants": []}, {"type_of_evidence": "Function", "drugs": [], "interactions": [], "effect": "Neomorphic", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "In the pancreatic cancer cell line PANC-1, R273H variant was shown to up-regulate chromatin regulatory genes, including methyltransferases KMT2A/MLL1, KMT2D/MLL2, and acetyltransferase KAT6A/MOZ, resulting in a genome-wide increase of histone methylation and acetylation, that may provide cancer cells with a selective growth advantage. This neomorphic function is dependent upon EST2-binding.", "support": "Strong", "comment": null, "references": "PMID:26331536", "annotations": [], "created_on": "2020-05-25T09:21:36.686Z", "last_modified": "2020-06-19T14:43:48.052Z", "status": "draft", "request_id": null, "disease": {"name": "Adenocarcinoma of pancreas", "localization": "PANCREAS", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R273H", "hgvs_c": "NM_000546.5:c.818G>A", "hgvs_p": "NP_000537.3:p.Arg273His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577120, "dbsnp_ids": ["28934576"]}, "extra_variants": []}, {"type_of_evidence": "Prognostic", "drugs": [], "interactions": [], "effect": "Poor outcome", "tier_level_criteria": "Population study", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Out of total number of 947 early-stage endometrioid endometrial carcinomas, Stelloo et al. identified a small subset bearing CTNNB1 mutations, including S45F in 12 tumors, which tended to exhibit  a more aggressive behavior.", "support": "Low", "comment": null, "references": "PMID:27006490", "annotations": [], "created_on": "2020-08-14T10:15:29.717Z", "last_modified": "2020-08-14T10:15:29.717Z", "status": "draft", "request_id": null, "disease": {"name": "Endometrioid adenocarcinoma", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "CTNNB1", "name": "S45F", "hgvs_c": "ENST00000349496:c.134C>T", "hgvs_p": null, "reference_name": "GrCh37", "chromosome": "chr3", "start_pos": 41266137, "dbsnp_ids": null}, "extra_variants": []}, {"type_of_evidence": "Function", "drugs": [], "interactions": [], "effect": "Gain of function", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "In endometrium adenocarcinoma KLE cells, R175H promotes cell migration and invasion. This effect involves the EGFR/PI3K/AKT pathway.", "support": "Moderate", "comment": null, "references": "PMID:19917135", "annotations": [], "created_on": "2020-05-29T11:42:23.757Z", "last_modified": "2020-05-29T12:10:22.554Z", "status": "draft", "request_id": null, "disease": {"name": "Neoplasm of endometrium", "localization": "ENDOMETRIUM", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R175H", "hgvs_c": "NM_000546.5:c.524G>A", "hgvs_p": "NP_000537.3:p.Arg175His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7578406, "dbsnp_ids": ["28934578"]}, "extra_variants": []}, {"type_of_evidence": "Function", "drugs": [], "interactions": [], "effect": "Neomorphic", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "In SK-BR-3 cell line harboring R175H TP53 variant, HER2/ERBB2 expression levels (at the mRNA and protein level) were much higher than those observed to cell lines either expressing wild-type TP53, or TP53-null.", "support": "Strong", "comment": null, "references": "PMID:29970031", "annotations": [], "created_on": "2020-06-10T13:34:15.751Z", "last_modified": "2020-06-10T16:11:09.948Z", "status": "draft", "request_id": null, "disease": {"name": "Carcinoma of breast", "localization": "BREAST", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R175H", "hgvs_c": "NM_000546.5:c.524G>A", "hgvs_p": "NP_000537.3:p.Arg175His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7578406, "dbsnp_ids": ["28934578"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["Paclitaxel"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Liver cancer cells Hep3B transfected with variant R248Q are resistant to paclitaxel compared to untransfected TP53-null cells or R273C transfected cells. The resistance may be possibly mediated through the upregulation of multiple resistance protein ABCB1/P-glycoprotein.", "support": "Moderate", "comment": null, "references": "PMID:15004724", "annotations": [], "created_on": "2020-06-12T16:27:09.472Z", "last_modified": "2020-06-12T16:44:26.470Z", "status": "draft", "request_id": null, "disease": {"name": "Neoplasm of liver", "localization": "LIVER", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R248Q", "hgvs_c": "NM_000546.5:c.743G>A", "hgvs_p": "NP_000537.3:p.Arg248Gln", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577538, "dbsnp_ids": ["11540652"]}, "extra_variants": []}, {"type_of_evidence": "Function", "drugs": [], "interactions": [], "effect": "Dominant negative", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "R273H TP53 variant can form mixed tetramers with the wild-type protein, hence affecting the overall TP53 DNA-binding ability and acting as a dominant-negative mutation. In acute myeloid leukemia cell lines K562 and MOLM13 expressing R273H variant, the strong dominant negative effect exerted by the mutation was measured at the transcriptional level. In addition, cells heterozygous for the missense mutation and TP53-null cells were equally resistant to daunorubicin-induced apoptosis.", "support": "Strong", "comment": null, "references": "PMID:31395785", "annotations": [], "created_on": "2020-05-22T13:04:14.509Z", "last_modified": "2020-06-17T19:00:06.951Z", "status": "draft", "request_id": null, "disease": {"name": "Acute myeloid leukemia, disease", "localization": "LEUKEMIA", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R273H", "hgvs_c": "NM_000546.5:c.818G>A", "hgvs_p": "NP_000537.3:p.Arg273His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577120, "dbsnp_ids": ["28934576"]}, "extra_variants": []}, {"type_of_evidence": "Variant identification", "drugs": [], "interactions": [], "effect": null, "tier_level_criteria": null, "tier_level": null, "mutation_origin": "Germline", "associated_mendelian_diseases": "Li-Fraumeni syndrome", "summary": null, "support": "Strong", "comment": null, "references": "PMID:1978757", "annotations": [], "created_on": "2020-06-17T13:41:20.138Z", "last_modified": "2020-09-23T13:48:19.048Z", "status": "draft", "request_id": null, "disease": null, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R248W", "hgvs_c": "NM_000546.5:c.742C>T", "hgvs_p": "NP_000537.3:p.Arg248Trp", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577539, "dbsnp_ids": ["121912651"]}, "extra_variants": []}, {"type_of_evidence": "Function", "drugs": [], "interactions": [], "effect": "Dominant negative", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": null, "support": "Low", "comment": null, "references": "PMID:27589690", "annotations": [], "created_on": "2020-05-29T09:53:43.421Z", "last_modified": "2020-05-29T09:53:43.421Z", "status": "draft", "request_id": null, "disease": null, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R273H", "hgvs_c": "NM_000546.5:c.818G>A", "hgvs_p": "NP_000537.3:p.Arg273His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577120, "dbsnp_ids": ["28934576"]}, "extra_variants": []}, {"type_of_evidence": "Prognostic", "drugs": [], "interactions": [], "effect": "Poor outcome", "tier_level_criteria": "Population study", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "This study was performed with 342 patients, diagnosed with endometrial cancer and treated by surgery, 120 of which had unspecified CTNNB1 exon 3 mutations, which could include S45F. The results show that in low grade, early stage endometrial cancer patients, CTNNB1 exon 3 mutations are associated with worse recurrence-free survival, suggesting that patients with CTNNB1 mutations may benefit from an adjuvant therapy.", "support": "Moderate", "comment": null, "references": "PMID:28281553", "annotations": [], "created_on": "2020-08-12T16:29:47.876Z", "last_modified": "2020-08-14T09:44:12.299Z", "status": "draft", "request_id": null, "disease": {"name": "Endometrioid adenocarcinoma", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "CTNNB1", "name": "S45F", "hgvs_c": "ENST00000349496:c.134C>T", "hgvs_p": null, "reference_name": "GrCh37", "chromosome": "chr3", "start_pos": 41266137, "dbsnp_ids": null}, "extra_variants": []}, {"type_of_evidence": "Subcellular location", "drugs": [], "interactions": [], "effect": "Increased physiological location", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "S45F shows strong to moderate nuclear staining in extra-peritoneal desmoid tumors.", "support": "Strong", "comment": null, "references": "PMID:28851389", "annotations": [], "created_on": "2020-08-14T16:20:54.405Z", "last_modified": "2020-08-14T16:33:09.728Z", "status": "draft", "request_id": null, "disease": {"name": "Aggressive fibromatosis", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "CTNNB1", "name": "S45F", "hgvs_c": "ENST00000349496:c.134C>T", "hgvs_p": null, "reference_name": "GrCh37", "chromosome": "chr3", "start_pos": 41266137, "dbsnp_ids": null}, "extra_variants": []}, {"type_of_evidence": "Variant identification", "drugs": [], "interactions": [], "effect": null, "tier_level_criteria": null, "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "The authors studied 220 hepatocellular carcinoma and 373 hepatocellular adenoma and observed equal distribution between both tumor types for alterations\nat residues T41 and S45. The variant at position 41 was almost exclusively T41A.", "support": "Strong", "comment": null, "references": "PMID:27177928", "annotations": [], "created_on": "2020-08-26T08:50:17.463Z", "last_modified": "2020-08-26T12:13:40.716Z", "status": "draft", "request_id": null, "disease": {"name": "Liver cell adenoma", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "CTNNB1", "name": "T41A", "hgvs_c": "ENST00000349496:c.121A>G", "hgvs_p": null, "reference_name": "GrCh37", "chromosome": "chr3", "start_pos": 41266124, "dbsnp_ids": null}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["Meloxicam"], "interactions": [], "effect": "Responsive", "tier_level_criteria": "Clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Contrary to S45F mutation, the presence of T41A did not impact the efficacy of  meloxicam treatment in patients with sporadic desmoid tumors. 16 T41A  patients were studied.", "support": "Moderate", "comment": "", "references": "PMID:24788118", "annotations": [], "created_on": "2020-07-03T15:49:21.964Z", "last_modified": "2020-07-16T15:24:50.838Z", "status": "draft", "request_id": null, "disease": {"name": "Aggressive fibromatosis", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "CTNNB1", "name": "T41A", "hgvs_c": "ENST00000349496:c.121A>G", "hgvs_p": null, "reference_name": "GrCh37", "chromosome": "chr3", "start_pos": 41266124, "dbsnp_ids": null}, "extra_variants": []}, {"type_of_evidence": "Function", "drugs": [], "interactions": [], "effect": "Unaltered function", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "In 2 cohorts (a Dutch cohort: 11 tumors with exon 3 wild-type CTNNB1, 38 tumors with T41A variant and 12 with  S45F variant and a French cohort:  14 tumors with exon 3 wild-type CTNNB1, 45 tumors with T41A variant and 34 with  S45F variant), quantitative RT-PCR could not demonstrate any differential expression in selected Wnt target genes, including AXIN1, DKK1 and CCND1. There are several caveats in this study, including at least 1. definition of wild-type as lack of exon 3 mutations, and 2. selection of a subset of Wnt target genes.", "support": "Low", "comment": null, "references": "PMID:30528042", "annotations": [], "created_on": "2020-08-21T15:33:58.155Z", "last_modified": "2020-08-28T13:05:13.229Z", "status": "draft", "request_id": null, "disease": {"name": "Aggressive fibromatosis", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "CTNNB1", "name": "T41A", "hgvs_c": "ENST00000349496:c.121A>G", "hgvs_p": null, "reference_name": "GrCh37", "chromosome": "chr3", "start_pos": 41266124, "dbsnp_ids": null}, "extra_variants": []}, {"type_of_evidence": "Prognostic", "drugs": [], "interactions": [], "effect": "Intermediate", "tier_level_criteria": "Population study", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "In 47 patients diagnosed with desmoid-type fibromatosis, CTNNB1 exon 3 mutation were identified in 39 cases (83 %), including S45F (18 %). There was no correlation between any specific CTNNB1 mutation and clinical outcome.", "support": "Low", "comment": "", "references": "PMID:22744289", "annotations": [], "created_on": "2020-07-10T12:28:00.406Z", "last_modified": "2020-08-13T14:40:28.300Z", "status": "draft", "request_id": null, "disease": {"name": "Aggressive fibromatosis", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "CTNNB1", "name": "S45F", "hgvs_c": "ENST00000349496:c.134C>T", "hgvs_p": null, "reference_name": "GrCh37", "chromosome": "chr3", "start_pos": 41266137, "dbsnp_ids": null}, "extra_variants": []}, {"type_of_evidence": "Prognostic", "drugs": [], "interactions": [], "effect": "Poor outcome", "tier_level_criteria": "Population study", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Tumors from 101 patients, diagnosed with extra-abdominal fibromatosis, were studied. 87% of the tumors exhibited CTNNB1 exon 3 mutations, including S45F in 36.5% of the cases. The patient underwent surgery, followed in most cases by radiotherapy. During a median 62 month follow-up period, 51 patients relapsed, 1 with a wild-type CTNNB1 tumor and 50 with  mutated CTNNB1. The 5-year recurrence-free survival was significantly worse in all mutated CTNNB1 tumors, including S45F, compared with wild-type tumors, but this poor outcome could not be related to a specific genotype, as there was no significant difference between T41A, S45F, or S45P mutants.", "support": "Moderate", "comment": "", "references": "PMID:20197769", "annotations": [], "created_on": "2020-07-07T16:09:24.100Z", "last_modified": "2020-08-13T14:41:05.510Z", "status": "draft", "request_id": null, "disease": {"name": "Aggressive fibromatosis", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "CTNNB1", "name": "S45F", "hgvs_c": "ENST00000349496:c.134C>T", "hgvs_p": null, "reference_name": "GrCh37", "chromosome": "chr3", "start_pos": 41266137, "dbsnp_ids": null}, "extra_variants": []}, {"type_of_evidence": "Prognostic", "drugs": [], "interactions": [], "effect": "Intermediate", "tier_level_criteria": "Population study", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "The study involved 101 patients diagnosed with aggressive fibromatosis, who underwent surgical resection of the tumors. CTNNB1 exon 3 mutations were detected in 76 patients (75%), predominantly T41A (49 patients). The 5-year risk of recurrence for T41A mutation was similar to that of wild-type (12.2% vs. 13.4%).", "support": "Moderate", "comment": "", "references": "PMID:25341748", "annotations": [], "created_on": "2020-07-10T15:56:29.182Z", "last_modified": "2020-08-13T14:44:33.883Z", "status": "draft", "request_id": null, "disease": {"name": "Aggressive fibromatosis", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "CTNNB1", "name": "T41A", "hgvs_c": "ENST00000349496:c.121A>G", "hgvs_p": null, "reference_name": "GrCh37", "chromosome": "chr3", "start_pos": 41266124, "dbsnp_ids": null}, "extra_variants": []}, {"type_of_evidence": "Prognostic", "drugs": [], "interactions": [], "effect": "Intermediate", "tier_level_criteria": "Population study", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "In 47 patients diagnosed with desmoid-type fibromatosis, CTNNB1 exon 3 mutation were identified in 39 cases (83 %), predominantly T41A (77 %). There was no correlation between any specific CTNNB1 mutation and clinical outcome.", "support": "Low", "comment": "", "references": "PMID:22744289", "annotations": [], "created_on": "2020-07-10T12:28:10.739Z", "last_modified": "2020-08-13T14:44:53.217Z", "status": "draft", "request_id": null, "disease": {"name": "Aggressive fibromatosis", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "CTNNB1", "name": "T41A", "hgvs_c": "ENST00000349496:c.121A>G", "hgvs_p": null, "reference_name": "GrCh37", "chromosome": "chr3", "start_pos": 41266124, "dbsnp_ids": null}, "extra_variants": []}, {"type_of_evidence": "Prognostic", "drugs": [], "interactions": [], "effect": "Intermediate", "tier_level_criteria": "Population study", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "The study involved 115 patients diagnosed with aggressive fibromatosis, who underwent surgical resection of the tumors. CTNNB1 exon 3 mutations were detected in 75% of the tumors, including T41A in 46%. At a median follow-up of 31 months, 5-year recurrence-free survival was slightly, although not statistically significantly, worse for patients with CTNNB1 mutated tumors than for those with wild-type tumors (58% vs. 74%, respectively). The specific CTNNB1 codon mutation (A41T or S45F) did not correlate with the risk for recurrence.", "support": "Moderate", "comment": "", "references": "PMID:23960186", "annotations": [], "created_on": "2020-07-10T11:57:29.700Z", "last_modified": "2020-08-13T14:45:12.174Z", "status": "draft", "request_id": null, "disease": {"name": "Aggressive fibromatosis", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "CTNNB1", "name": "T41A", "hgvs_c": "ENST00000349496:c.121A>G", "hgvs_p": null, "reference_name": "GrCh37", "chromosome": "chr3", "start_pos": 41266124, "dbsnp_ids": null}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["Meloxicam"], "interactions": [], "effect": "Not responsive", "tier_level_criteria": "Case reports", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Contrary to T41A and S45P mutations, that did not impact treatment, the presence of S45F was significantly associated with a poor response  to meloxicam in patients with sporadic desmoid tumors . Caveat: only 4 S45F patients were studied.", "support": "Low", "comment": "", "references": "PMID:24788118", "annotations": [], "created_on": "2020-07-03T15:38:47.646Z", "last_modified": "2020-09-04T15:30:00.137Z", "status": "draft", "request_id": null, "disease": {"name": "Aggressive fibromatosis", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "CTNNB1", "name": "S45F", "hgvs_c": "ENST00000349496:c.134C>T", "hgvs_p": null, "reference_name": "GrCh37", "chromosome": "chr3", "start_pos": 41266137, "dbsnp_ids": null}, "extra_variants": []}, {"type_of_evidence": "Interaction", "drugs": [], "interactions": ["CTNNA1"], "effect": "Decreased interaction with known partner(s)", "tier_level_criteria": "Prediction", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "CTNNB1 residues T41 and S45 are predicted play an active role in the complex formation with CTNNA1 and their mutation might decrease binding affinity.", "support": "Low", "comment": "", "references": "PMID:28627792", "annotations": [], "created_on": "2020-07-06T15:05:46.080Z", "last_modified": "2020-09-22T13:21:31.642Z", "status": "draft", "request_id": null, "disease": null, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "CTNNB1", "name": "S45F", "hgvs_c": "ENST00000349496:c.134C>T", "hgvs_p": null, "reference_name": "GrCh37", "chromosome": "chr3", "start_pos": 41266137, "dbsnp_ids": null}, "extra_variants": []}, {"type_of_evidence": "Prognostic", "drugs": [], "interactions": [], "effect": "Poor outcome", "tier_level_criteria": "Population study", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Tumors from 101 patients, diagnosed with extra-abdominal fibromatosis, were studied. 87% of the tumors exhibited CTNNB1 exon 3 mutations, including T41A in 39.5% of the cases. The patient underwent surgery, followed in most cases by radiotherapy. During a median 62 month follow-up period, 51 patients relapsed, 1 with a wild-type CTNNB1 tumor and 50 with  mutated CTNNB1. The 5-year recurrence-free survival was significantly shorter in all mutated CTNNB1 tumors, including T41A, compared with wild-type tumors, but this poor outcome could not be related to a specific genotype, as there was no significant difference between T41A, S45F, or S45P mutants.", "support": "Moderate", "comment": "", "references": "PMID:20197769", "annotations": [], "created_on": "2020-07-07T15:51:11.326Z", "last_modified": "2020-08-13T14:45:38.945Z", "status": "draft", "request_id": null, "disease": {"name": "Aggressive fibromatosis", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "CTNNB1", "name": "T41A", "hgvs_c": "ENST00000349496:c.121A>G", "hgvs_p": null, "reference_name": "GrCh37", "chromosome": "chr3", "start_pos": 41266124, "dbsnp_ids": null}, "extra_variants": []}, {"type_of_evidence": "Prognostic", "drugs": [], "interactions": [], "effect": "Poor outcome", "tier_level_criteria": "Population study", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "This study was performed with 342 patients, diagnosed with endometrial cancer and treated by surgery, 120 of which had unspecified CTNNB1 exon 3 mutations, which could include T41A. The results show that in low grade, early stage endometrial cancer patients, CTNNB1 exon 3 mutations are associated with worse recurrence-free survival, suggesting that patients with CTNNB1 mutations may benefit from an adjuvant therapy.", "support": "Moderate", "comment": null, "references": "PMID:28281553", "annotations": [], "created_on": "2020-08-12T16:30:35.724Z", "last_modified": "2020-08-14T09:44:14.349Z", "status": "draft", "request_id": null, "disease": {"name": "Endometrioid adenocarcinoma", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "CTNNB1", "name": "T41A", "hgvs_c": "ENST00000349496:c.121A>G", "hgvs_p": null, "reference_name": "GrCh37", "chromosome": "chr3", "start_pos": 41266124, "dbsnp_ids": null}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["Meloxicam"], "interactions": [], "effect": "Other", "tier_level_criteria": "Case reports", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "In 17 patients diagnosed with extra-peritoneal desmoid fibromatosis, the presence of T41A variant did not affect the response to meloxicam treatment.", "support": "Low", "comment": null, "references": "PMID:28851389", "annotations": [], "created_on": "2020-08-14T16:33:00.393Z", "last_modified": "2020-08-14T16:33:00.393Z", "status": "draft", "request_id": null, "disease": {"name": "Aggressive fibromatosis", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "CTNNB1", "name": "T41A", "hgvs_c": "ENST00000349496:c.121A>G", "hgvs_p": null, "reference_name": "GrCh37", "chromosome": "chr3", "start_pos": 41266124, "dbsnp_ids": null}, "extra_variants": []}, {"type_of_evidence": "Function", "drugs": [], "interactions": [], "effect": "Gain of function", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Expression of CTNNB1 target genes GLUL and LGR5 was moderately increased in T41A-mutated hepotocellular adenomas. Such an increase in CTNNB1-mediated gene expression was also observed when T41A-mutated CTNNB1 was transfected into various cell lines.", "support": "Strong", "comment": null, "references": "PMID:27177928", "annotations": [], "created_on": "2020-08-26T10:02:44.879Z", "last_modified": "2020-08-26T12:30:46.667Z", "status": "draft", "request_id": null, "disease": {"name": "Liver cell adenoma", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "CTNNB1", "name": "T41A", "hgvs_c": "ENST00000349496:c.121A>G", "hgvs_p": null, "reference_name": "GrCh37", "chromosome": "chr3", "start_pos": 41266124, "dbsnp_ids": null}, "extra_variants": []}, {"type_of_evidence": "Subcellular location", "drugs": [], "interactions": [], "effect": "Increased physiological location", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Desmoid tumor biopsies exhibit strong CTNNB1 nuclear staining.", "support": "Strong", "comment": "", "references": "PMID:24788118", "annotations": [], "created_on": "2020-07-03T15:44:37.089Z", "last_modified": "2020-07-16T09:08:59.914Z", "status": "draft", "request_id": null, "disease": {"name": "Aggressive fibromatosis", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "CTNNB1", "name": "S45F", "hgvs_c": "ENST00000349496:c.134C>T", "hgvs_p": null, "reference_name": "GrCh37", "chromosome": "chr3", "start_pos": 41266137, "dbsnp_ids": null}, "extra_variants": []}, {"type_of_evidence": "Prognostic", "drugs": [], "interactions": [], "effect": "Poor outcome", "tier_level_criteria": "Included in Professional Guidelines", "tier_level": "Tier IA", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "CTNNB1 S45F mutation by polymerase chain reaction is recommended as a prognostic factor for poor recurrence-free survival in patients with desmoid tumours by the Cancer Care Ontario\u2019s Program in Evidence-Based Care (PEBC) and the Sarcoma Disease Site Group (DSG). This is considered as a strong recommendation by the working group.", "support": "Strong", "comment": "", "references": "PMID:32092619", "annotations": [], "created_on": "2020-07-15T16:01:20.552Z", "last_modified": "2020-07-16T09:34:36.471Z", "status": "draft", "request_id": null, "disease": {"name": "Aggressive fibromatosis", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "CTNNB1", "name": "S45F", "hgvs_c": "ENST00000349496:c.134C>T", "hgvs_p": null, "reference_name": "GrCh37", "chromosome": "chr3", "start_pos": 41266137, "dbsnp_ids": null}, "extra_variants": []}, {"type_of_evidence": "Variant identification", "drugs": [], "interactions": [], "effect": null, "tier_level_criteria": null, "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "In 179 patients diagnosed with desmoid fibromatosis, the T41A mutation was the most frequent (45%).", "support": "Strong", "comment": "", "references": "PMID:23913621", "annotations": [], "created_on": "2020-07-13T08:56:48.879Z", "last_modified": "2020-07-16T15:20:12.819Z", "status": "draft", "request_id": null, "disease": {"name": "Aggressive fibromatosis", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "CTNNB1", "name": "T41A", "hgvs_c": "ENST00000349496:c.121A>G", "hgvs_p": null, "reference_name": "GrCh37", "chromosome": "chr3", "start_pos": 41266124, "dbsnp_ids": null}, "extra_variants": []}, {"type_of_evidence": "Interaction", "drugs": [], "interactions": [], "effect": "Decreased interaction with known partner(s)", "tier_level_criteria": "Prediction", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "CTNNB1 residues T41 and S45 are predicted play an active role in the complex formation with CTNNA1 and their mutation might decrease binding affinity.", "support": "Low", "comment": "", "references": "PMID:28627792", "annotations": [], "created_on": "2020-07-06T15:05:38.904Z", "last_modified": "2020-07-16T15:24:22.136Z", "status": "draft", "request_id": null, "disease": null, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "CTNNB1", "name": "T41A", "hgvs_c": "ENST00000349496:c.121A>G", "hgvs_p": null, "reference_name": "GrCh37", "chromosome": "chr3", "start_pos": 41266124, "dbsnp_ids": null}, "extra_variants": []}, {"type_of_evidence": "Subcellular location", "drugs": [], "interactions": [], "effect": "New location", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Desmoid tumor biopsies exhibit moderate to strong CTNNB1  nuclear staining.", "support": "Strong", "comment": "", "references": "PMID:24788118", "annotations": [], "created_on": "2020-07-03T15:52:03.498Z", "last_modified": "2020-07-16T15:24:36.796Z", "status": "draft", "request_id": null, "disease": {"name": "Aggressive fibromatosis", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "CTNNB1", "name": "T41A", "hgvs_c": "ENST00000349496:c.121A>G", "hgvs_p": null, "reference_name": "GrCh37", "chromosome": "chr3", "start_pos": 41266124, "dbsnp_ids": null}, "extra_variants": []}, {"type_of_evidence": "Response to drug", "drugs": ["MSAB"], "interactions": [], "effect": "Newly acquired drug response", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Methyl 3-{[(4-methyl phenyl) sulfonyl] amino} benzoate (MSAB) was able to bind to CTNNB1 and induce its proteasomal degradation. MSAB selectively affected Wnt/CTNNB1-dependent transcriptional activity, Wnt-mediated cell proliferation and inhibited growth of Wnt/CTNNB1-dependent xenograft tumors in mice, most probably by inducing apoptotic cell death. The cell model used in these experiments was the colon carcinoma HCT116 cell line, which bears a deletion of CTNNB1 Ser-45 codon, and the colon adenocarcinoma LS174T cell line, which expresses p.Ser45Phe mutation.", "support": "Moderate", "comment": null, "references": "PMID:27320923", "annotations": [], "created_on": "2020-08-11T15:58:31.202Z", "last_modified": "2020-08-13T08:29:21.691Z", "status": "draft", "request_id": null, "disease": {"name": "Adenocarcinoma of colorectum", "localization": "COLORECTUM", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "CTNNB1", "name": "S45F", "hgvs_c": "ENST00000349496:c.134C>T", "hgvs_p": null, "reference_name": "GrCh37", "chromosome": "chr3", "start_pos": 41266137, "dbsnp_ids": null}, "extra_variants": []}, {"type_of_evidence": "Prognostic", "drugs": [], "interactions": [], "effect": "Poor outcome", "tier_level_criteria": "Population study", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "The study involved 101 patients diagnosed with aggressive fibromatosis, who underwent surgical resection of the tumors. CTNNB1 exon 3 mutations were detected in 76 patients (75%), including S45F (18 patients). The presence of a S45F mutation was associated with a 5-year cumulative risk of recurrence of 63.8 %. Patients with S45F tumors had an 8.5-fold higher risk of recurrence than patients with tumors that were wild type.", "support": "Moderate", "comment": "", "references": "PMID:25341748", "annotations": [], "created_on": "2020-07-10T12:53:51.364Z", "last_modified": "2020-08-13T14:42:00.714Z", "status": "draft", "request_id": null, "disease": {"name": "Aggressive fibromatosis", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "CTNNB1", "name": "S45F", "hgvs_c": "ENST00000349496:c.134C>T", "hgvs_p": null, "reference_name": "GrCh37", "chromosome": "chr3", "start_pos": 41266137, "dbsnp_ids": null}, "extra_variants": []}, {"type_of_evidence": "Prognostic", "drugs": [], "interactions": [], "effect": "Poor outcome", "tier_level_criteria": "Population study", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Recurrence-free survival after initial complete surgical resection was significantly inferior for patients bearing tumors with the S45F genotype. The estimated 5-year recurrence-free survival rate was 23% for patients with S45F mutation compared to 57% for T41A mutation, and 65% for wild-type CTNNB1.", "support": "Strong", "comment": "", "references": "PMID:18832571", "annotations": [], "created_on": "2020-07-13T15:31:34.265Z", "last_modified": "2020-08-13T14:42:22.974Z", "status": "draft", "request_id": null, "disease": {"name": "Aggressive fibromatosis", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "CTNNB1", "name": "S45F", "hgvs_c": "ENST00000349496:c.134C>T", "hgvs_p": null, "reference_name": "GrCh37", "chromosome": "chr3", "start_pos": 41266137, "dbsnp_ids": null}, "extra_variants": []}, {"type_of_evidence": "Prognostic", "drugs": [], "interactions": [], "effect": "Intermediate", "tier_level_criteria": "Population study", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Recurrence-free survival after initial complete surgical resection was not significantly different between patients bearing T41A or wild-type tumors. The estimated 5-year recurrence-free survival rate was 57% for patients withT41A mutation compared to 65% for wild-type CTNNB1.", "support": "Strong", "comment": null, "references": "PMID:18832571", "annotations": [], "created_on": "2020-07-13T15:37:30.480Z", "last_modified": "2020-08-13T14:43:41.181Z", "status": "draft", "request_id": null, "disease": {"name": "Aggressive fibromatosis", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "CTNNB1", "name": "T41A", "hgvs_c": "ENST00000349496:c.121A>G", "hgvs_p": null, "reference_name": "GrCh37", "chromosome": "chr3", "start_pos": 41266124, "dbsnp_ids": null}, "extra_variants": []}, {"type_of_evidence": "Prognostic", "drugs": [], "interactions": [], "effect": "Poor outcome", "tier_level_criteria": "Population study", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "In patients diagnosed with desmoid tumors, there was a trend to lower estimated 3-year and 5-year recurrence-free survival (RFS) rates for T41A mutant tumors as compared to wild-type CTNNB1 tumors, though this difference may not be statistically significant.  This also holds true for patients who underwent surgery, but there was no difference in RFS for patients who underwent surgery and received other treatments, such as radiotherapy, chemotherapy (frequently methotrexate and vinorelbine), medical therapy/hormone agents (tamoxifen, toremifene), and nonsteroidal anti-inflammatory drugs (cyclooxygenase-2 inhibitors).", "support": "Low", "comment": "", "references": "PMID:23913621", "annotations": [], "created_on": "2020-07-13T10:03:01.395Z", "last_modified": "2020-08-13T14:44:10.261Z", "status": "draft", "request_id": null, "disease": {"name": "Aggressive fibromatosis", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "CTNNB1", "name": "T41A", "hgvs_c": "ENST00000349496:c.121A>G", "hgvs_p": null, "reference_name": "GrCh37", "chromosome": "chr3", "start_pos": 41266124, "dbsnp_ids": null}, "extra_variants": []}, {"type_of_evidence": "Prognostic", "drugs": [], "interactions": [], "effect": "Poor outcome", "tier_level_criteria": "Case reports", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "In 3 patients diagnosed with extra-peritoneal desmoid fibromatosis, the presence of S45F variant was associated with poor response to meloxicam treatment.", "support": "Low", "comment": null, "references": "PMID:28851389", "annotations": [], "created_on": "2020-08-14T16:34:18.838Z", "last_modified": "2020-08-14T16:34:18.839Z", "status": "draft", "request_id": null, "disease": {"name": "Aggressive fibromatosis", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "CTNNB1", "name": "S45F", "hgvs_c": "ENST00000349496:c.134C>T", "hgvs_p": null, "reference_name": "GrCh37", "chromosome": "chr3", "start_pos": 41266137, "dbsnp_ids": null}, "extra_variants": []}, {"type_of_evidence": "Diagnostic", "drugs": [], "interactions": [], "effect": "Associated with diagnosis", "tier_level_criteria": "Included in Professional Guidelines", "tier_level": "Tier IA", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "The presence of CTNNB1 mutation may be a sensitive and specific test to differentiate patients with desmoid tumour from histological mimickers and sequencing is recommended by the Cancer Care Ontario\u2019s Program in Evidence-Based Care (PEBC) and the Sarcoma Disease Site Group (DSG).", "support": "Moderate", "comment": null, "references": "PMID:32092619", "annotations": [], "created_on": "2020-07-16T09:16:57.200Z", "last_modified": "2020-08-25T14:36:40.377Z", "status": "submitted", "request_id": null, "disease": {"name": "Aggressive fibromatosis", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "CTNNB1", "name": "T41A", "hgvs_c": "ENST00000349496:c.121A>G", "hgvs_p": null, "reference_name": "GrCh37", "chromosome": "chr3", "start_pos": 41266124, "dbsnp_ids": null}, "extra_variants": []}, {"type_of_evidence": "Subcellular location", "drugs": [], "interactions": [], "effect": "Increased physiological location", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "CTNNB1 nuclear localization is increased in hepatocellular adenoma cells carrying T41A variant.", "support": "Strong", "comment": "", "references": "PMID:27177928", "annotations": [], "created_on": "2020-08-26T13:00:20.724Z", "last_modified": "2020-08-26T13:06:59.282Z", "status": "draft", "request_id": null, "disease": {"name": "Liver cell adenoma", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "CTNNB1", "name": "T41A", "hgvs_c": "ENST00000349496:c.121A>G", "hgvs_p": null, "reference_name": "GrCh37", "chromosome": "chr3", "start_pos": 41266124, "dbsnp_ids": null}, "extra_variants": []}, {"type_of_evidence": "Variant identification", "drugs": [], "interactions": [], "effect": null, "tier_level_criteria": null, "tier_level": null, "mutation_origin": "Somatic", "associated_mendelian_diseases": null, "summary": "In 138 sporadic desmoid tumors, CTNNB1 mutation S45F was identified in 33% of the samples.", "support": "Strong", "comment": "", "references": "PMID:18832571", "annotations": [], "created_on": "2020-07-13T15:04:58.254Z", "last_modified": "2020-07-16T08:34:15.839Z", "status": "draft", "request_id": null, "disease": {"name": "Aggressive fibromatosis", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "CTNNB1", "name": "S45F", "hgvs_c": "ENST00000349496:c.134C>T", "hgvs_p": null, "reference_name": "GrCh37", "chromosome": "chr3", "start_pos": 41266137, "dbsnp_ids": null}, "extra_variants": []}, {"type_of_evidence": "Variant identification", "drugs": [], "interactions": [], "effect": null, "tier_level_criteria": null, "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "In 179 patients diagnosed with desmoid fibromatosis, the S45F mutation was significantly more prevalent in extra-abdominal sites compared with other locations. Moreover, the percentage of S45F-mutated desmoid tumors increased with increasing tumor size.", "support": "Strong", "comment": "", "references": "PMID:23913621", "annotations": [], "created_on": "2020-07-13T10:03:46.456Z", "last_modified": "2020-07-16T08:39:26.770Z", "status": "draft", "request_id": null, "disease": {"name": "Aggressive fibromatosis", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "CTNNB1", "name": "S45F", "hgvs_c": "ENST00000349496:c.134C>T", "hgvs_p": null, "reference_name": "GrCh37", "chromosome": "chr3", "start_pos": 41266137, "dbsnp_ids": null}, "extra_variants": []}, {"type_of_evidence": "Subcellular location", "drugs": [], "interactions": [], "effect": "Increased physiological location", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": "Somatic", "associated_mendelian_diseases": null, "summary": "Nuclear CTNNB1 localization was observed by immunohistochemistry in 98% of desmoid samples, compared to scars expressing wild-type CTNNB1, in which very focal, weak nuclear reactivity was observed in a very limited number of samples.", "support": null, "comment": "", "references": "PMID:18832571", "annotations": [], "created_on": "2020-07-13T16:14:46.372Z", "last_modified": "2020-07-16T08:51:22.880Z", "status": "draft", "request_id": null, "disease": {"name": "Aggressive fibromatosis", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "CTNNB1", "name": "S45F", "hgvs_c": "ENST00000349496:c.134C>T", "hgvs_p": null, "reference_name": "GrCh37", "chromosome": "chr3", "start_pos": 41266137, "dbsnp_ids": null}, "extra_variants": []}, {"type_of_evidence": "Subcellular location", "drugs": [], "interactions": [], "effect": "Increased physiological location", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": "Somatic", "associated_mendelian_diseases": null, "summary": "Nuclear CTNNB1 localization was observed by immunohistochemistry in 98% of desmoid samples, compared to scars expressing wild-type CTNNB1, in which very focal, weak nuclear reactivity was observed in a very limited number of samples.", "support": null, "comment": "", "references": "PMID:18832571", "annotations": [], "created_on": "2020-07-13T16:14:37.514Z", "last_modified": "2020-07-16T15:18:51.932Z", "status": "draft", "request_id": null, "disease": {"name": "Aggressive fibromatosis", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "CTNNB1", "name": "T41A", "hgvs_c": "ENST00000349496:c.121A>G", "hgvs_p": null, "reference_name": "GrCh37", "chromosome": "chr3", "start_pos": 41266124, "dbsnp_ids": null}, "extra_variants": []}, {"type_of_evidence": "Variant identification", "drugs": [], "interactions": [], "effect": null, "tier_level_criteria": null, "tier_level": null, "mutation_origin": "Somatic", "associated_mendelian_diseases": null, "summary": "In 138 sporadic desmoid tumors, CTNNB1 mutation T41A was identified in 59% of the samples.", "support": "Strong", "comment": "", "references": "PMID:18832571", "annotations": [], "created_on": "2020-07-13T15:07:01.036Z", "last_modified": "2020-07-16T15:19:26.745Z", "status": "draft", "request_id": null, "disease": {"name": "Aggressive fibromatosis", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "CTNNB1", "name": "T41A", "hgvs_c": "ENST00000349496:c.121A>G", "hgvs_p": null, "reference_name": "GrCh37", "chromosome": "chr3", "start_pos": 41266124, "dbsnp_ids": null}, "extra_variants": []}, {"type_of_evidence": "Variant identification", "drugs": [], "interactions": [], "effect": "Unknown", "tier_level_criteria": "None", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Variant S45F was identified in a single adrenal cortical carcinoma sample out of 61 analyzed.", "support": "Moderate", "comment": null, "references": "PMID:29872083", "annotations": [], "created_on": "2020-08-07T15:11:05.324Z", "last_modified": "2020-08-07T15:30:15.176Z", "status": "draft", "request_id": null, "disease": {"name": "Adrenal cortical carcinoma", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "CTNNB1", "name": "S45F", "hgvs_c": "ENST00000349496:c.134C>T", "hgvs_p": null, "reference_name": "GrCh37", "chromosome": "chr3", "start_pos": 41266137, "dbsnp_ids": null}, "extra_variants": []}, {"type_of_evidence": "Prognostic", "drugs": [], "interactions": [], "effect": "Intermediate", "tier_level_criteria": "Population study", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "The study involved 115 patients diagnosed with aggressive fibromatosis, who underwent surgical resection of the tumors. CTNNB1 exon 3 mutations were detected in 75% of the tumors, including S45F in 25%. At a median follow-up of 31 months, 5-year recurrence-free survival was slightly, although not statistically significantly, worse for patients with CTNNB1 mutated tumors than for those with wild-type tumors (58% vs. 74%, respectively). The specific CTNNB1 codon mutation (A41T or S45F) did not correlate with the risk for recurrence.", "support": "Moderate", "comment": "", "references": "PMID:23960186", "annotations": [], "created_on": "2020-07-10T11:58:23.175Z", "last_modified": "2020-08-13T14:40:50.667Z", "status": "draft", "request_id": null, "disease": {"name": "Aggressive fibromatosis", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "CTNNB1", "name": "S45F", "hgvs_c": "ENST00000349496:c.134C>T", "hgvs_p": null, "reference_name": "GrCh37", "chromosome": "chr3", "start_pos": 41266137, "dbsnp_ids": null}, "extra_variants": []}, {"type_of_evidence": "Diagnostic", "drugs": [], "interactions": [], "effect": "Associated with diagnosis", "tier_level_criteria": "Included in Professional Guidelines", "tier_level": "Tier IA", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Approximately 85%\u201390% of desmoid-type fibromatosis (DF) harbors mutations in the CTNNB1 gene (predominantly T41A in roughly 50% of the cases), leading to nuclear accumulation of CTNNB1-encoded protein. CTNNB1 mutations and APC mutations appear to be mutually exclusive in DF, thus, detection of a somatic CTNNB1 mutation may help to exclude a syndromal condition. Vice versa, CTNNB1 wild-type status in DF should raise suspicion for familial adenomatous polyposis (FAP), with more extensive diagnostic clinical work-up (e.g. colonoscopy). Mutation analysis of CTNNB1 has been proposed as a specific diagnostic tool for establishing DF diagnosis, particularly in challenging or diagnostically ambiguous cases (recommendation issued  by the European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG)).", "support": "Moderate", "comment": null, "references": "PMID:28961825", "annotations": [], "created_on": "2020-07-16T12:44:57.269Z", "last_modified": "2020-07-16T13:40:11.544Z", "status": "draft", "request_id": null, "disease": {"name": "Aggressive fibromatosis", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "CTNNB1", "name": "T41A", "hgvs_c": "ENST00000349496:c.121A>G", "hgvs_p": null, "reference_name": "GrCh37", "chromosome": "chr3", "start_pos": 41266124, "dbsnp_ids": null}, "extra_variants": []}, {"type_of_evidence": "Diagnostic", "drugs": [], "interactions": [], "effect": "Associated with diagnosis", "tier_level_criteria": "Included in Professional Guidelines", "tier_level": "Tier IA", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Approximately 85%\u201390% of desmoid-type fibromatosis (DF) harbors mutations in the CTNNB1 gene (S45F in roughly 25% of the cases), leading to nuclear accumulation of CTNNB1-encoded protein. CTNNB1 mutations and APC mutations appear to be mutually exclusive in DF, thus, detection of a somatic CTNNB1 mutation may help to exclude a syndromal condition. Vice versa, CTNNB1 wild-type status in DF should raise suspicion for familial adenomatous polyposis (FAP), with more extensive diagnostic clinical work-up (e.g. colonoscopy). Mutation analysis of CTNNB1 has been proposed as a specific diagnostic tool for establishing DF diagnosis, particularly in challenging or diagnostically ambiguous cases (recommendation issued  by the European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG)).", "support": "Moderate", "comment": null, "references": "PMID:28961825", "annotations": [], "created_on": "2020-07-16T13:39:51.159Z", "last_modified": "2020-07-16T13:50:08.772Z", "status": "draft", "request_id": null, "disease": {"name": "Aggressive fibromatosis", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "CTNNB1", "name": "S45F", "hgvs_c": "ENST00000349496:c.134C>T", "hgvs_p": null, "reference_name": "GrCh37", "chromosome": "chr3", "start_pos": 41266137, "dbsnp_ids": null}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["Imatinib"], "interactions": [], "effect": "Responsive", "tier_level_criteria": "Population study", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "The authors show a positive correlation of the CTNNB1 mutation status with the progression arrest rate after 6 months of therapy with imatinib.  The highest progression arrest rate (PAR) of 85 % could be demonstrated in patients with the S45F mutation. Patients with wild-type CTNNB1 tumors exhibit a PAR of 43%. This observation supports imatinib as a viable treatment option in desmoid fibromatosis harboring CTNNB1 mutations. Caveat: only 13 patients bearing an S45F positive tumor.", "support": "Low", "comment": "", "references": "PMID:26861905", "annotations": [], "created_on": "2020-07-13T13:24:27.442Z", "last_modified": "2020-09-04T15:29:33.122Z", "status": "draft", "request_id": null, "disease": {"name": "Aggressive fibromatosis", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "CTNNB1", "name": "S45F", "hgvs_c": "ENST00000349496:c.134C>T", "hgvs_p": null, "reference_name": "GrCh37", "chromosome": "chr3", "start_pos": 41266137, "dbsnp_ids": null}, "extra_variants": []}, {"type_of_evidence": "Prognostic", "drugs": [], "interactions": [], "effect": "Poor outcome", "tier_level_criteria": "Included in Professional Guidelines", "tier_level": "Tier IA", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Based on several publications (available from SVIP-O database), the European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG) encourages CTNNB1 S45F mutation analysis in desmoid-type fibromatosis to identify patients with a probably more aggressive course.", "support": "Low", "comment": null, "references": "PMID:28961825", "annotations": [], "created_on": "2020-07-16T13:44:20.816Z", "last_modified": "2020-07-16T13:50:55.051Z", "status": "draft", "request_id": null, "disease": {"name": "Aggressive fibromatosis", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "CTNNB1", "name": "S45F", "hgvs_c": "ENST00000349496:c.134C>T", "hgvs_p": null, "reference_name": "GrCh37", "chromosome": "chr3", "start_pos": 41266137, "dbsnp_ids": null}, "extra_variants": []}, {"type_of_evidence": "Diagnostic", "drugs": [], "interactions": [], "effect": "Associated with diagnosis", "tier_level_criteria": "Included in Professional Guidelines", "tier_level": "Tier IA", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "The presence of CTNNB1 mutation may be a sensitive and specific test to differentiate patients with desmoid tumour from histological mimickers and sequencing is recommended by the Cancer Care Ontario\u2019s Program in Evidence-Based Care (PEBC) and the Sarcoma Disease Site Group (DSG).", "support": "Moderate", "comment": null, "references": "PMID:32092619", "annotations": [], "created_on": "2020-07-16T09:15:41.734Z", "last_modified": "2020-07-16T13:55:42.711Z", "status": "draft", "request_id": null, "disease": {"name": "Aggressive fibromatosis", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "CTNNB1", "name": "S45F", "hgvs_c": "ENST00000349496:c.134C>T", "hgvs_p": null, "reference_name": "GrCh37", "chromosome": "chr3", "start_pos": 41266137, "dbsnp_ids": null}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["sorafenib", "Hydroxychloroquine"], "interactions": [], "effect": "Sensitive (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Treatment of S45F-mutated primary desmoid tumor cells with a combination of sorafenib with hydroxychloroquine (a medically approved inhibitor of lysosomal function) showed inhibition of cell growth and increased apoptosis, compared with treatment with either sorafenib or hydroxychloroquine alone. This effect was not observed not in T41A-mutated cells.", "support": "Low", "comment": null, "references": "PMID:30980399", "annotations": [], "created_on": "2020-07-16T16:37:00.177Z", "last_modified": "2020-07-16T16:37:00.177Z", "status": "draft", "request_id": null, "disease": {"name": "Aggressive fibromatosis", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "CTNNB1", "name": "S45F", "hgvs_c": "ENST00000349496:c.134C>T", "hgvs_p": null, "reference_name": "GrCh37", "chromosome": "chr3", "start_pos": 41266137, "dbsnp_ids": null}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["Hydroxychloroquine"], "interactions": [], "effect": "Sensitive (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "In S45F-mutated primary desmoid tumor cells, hydroxychloroquine alone produced decreased cell growth and induction of caspase-dependent apoptosis, but had no effect on T41A-mutated desmoid tumor cells.", "support": "Low", "comment": null, "references": "PMID:30980399", "annotations": [], "created_on": "2020-07-16T16:28:24.403Z", "last_modified": "2020-07-16T16:37:55.553Z", "status": "draft", "request_id": null, "disease": {"name": "Aggressive fibromatosis", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "CTNNB1", "name": "S45F", "hgvs_c": "ENST00000349496:c.134C>T", "hgvs_p": null, "reference_name": "GrCh37", "chromosome": "chr3", "start_pos": 41266137, "dbsnp_ids": null}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["sorafenib"], "interactions": [], "effect": "Reduced sensitivity", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "In primary cell cultures, S45F-mutated desmoid cells were more tolerant - in terms of cell viability (apoptosis), invasion and migration - to sorafenib at a concentration of 1 \u03bcM than cells harboring T41A-mutated or wild-type CTNNB1. At higher concentrations, there was no apparent difference between the various CTNNB1 genotypes.", "support": "Low", "comment": null, "references": "PMID:30980399", "annotations": [], "created_on": "2020-07-16T15:08:37.486Z", "last_modified": "2020-07-16T16:38:11.107Z", "status": "draft", "request_id": null, "disease": {"name": "Aggressive fibromatosis", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "CTNNB1", "name": "S45F", "hgvs_c": "ENST00000349496:c.134C>T", "hgvs_p": null, "reference_name": "GrCh37", "chromosome": "chr3", "start_pos": 41266137, "dbsnp_ids": null}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["sorafenib"], "interactions": [], "effect": "Sensitive (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "In primary cell cultures, T41A-mutated desmoid cells were sensitive - in terms of cell viability (apoptosis), invasion and migration - to sorafenib.", "support": "Low", "comment": null, "references": "PMID:30980399", "annotations": [], "created_on": "2020-07-16T15:07:39.905Z", "last_modified": "2020-07-16T16:38:18.888Z", "status": "draft", "request_id": null, "disease": {"name": "Aggressive fibromatosis", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "CTNNB1", "name": "T41A", "hgvs_c": "ENST00000349496:c.121A>G", "hgvs_p": null, "reference_name": "GrCh37", "chromosome": "chr3", "start_pos": 41266124, "dbsnp_ids": null}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["bafilomycin"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Treatment of T41A-mutated primary desmoid tumor cells with bafilomycin did not have any effect.", "support": "Low", "comment": null, "references": "PMID:30980399", "annotations": [], "created_on": "2020-07-16T16:02:23.776Z", "last_modified": "2020-07-16T16:38:30.217Z", "status": "draft", "request_id": null, "disease": {"name": "Aggressive fibromatosis", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "CTNNB1", "name": "T41A", "hgvs_c": "ENST00000349496:c.121A>G", "hgvs_p": null, "reference_name": "GrCh37", "chromosome": "chr3", "start_pos": 41266124, "dbsnp_ids": null}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["Hydroxychloroquine"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Treatment of T41A-mutated primary desmoid tumor cells with hydroxychloroquine did not have any effect.", "support": "Low", "comment": null, "references": "PMID:30980399", "annotations": [], "created_on": "2020-07-16T16:28:13.335Z", "last_modified": "2020-07-16T16:38:37.251Z", "status": "draft", "request_id": null, "disease": {"name": "Aggressive fibromatosis", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "CTNNB1", "name": "T41A", "hgvs_c": "ENST00000349496:c.121A>G", "hgvs_p": null, "reference_name": "GrCh37", "chromosome": "chr3", "start_pos": 41266124, "dbsnp_ids": null}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["bafilomycin"], "interactions": [], "effect": "Sensitive (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Treatment of S45F-mutated primary desmoid tumor cells with bafilomycin (a potent inhibitor of cellular autophagy) alone led to an increase of cell death , whereas no effect was seen in T41A-mutated desmoid tumor cells. The involvement of autophagy in S45F-mutated cell survival mechanism was further supported by ATG5 knockdown, which also showed the induction of cell death.", "support": "Low", "comment": "", "references": "PMID:30980399", "annotations": [], "created_on": "2020-07-16T16:05:30.947Z", "last_modified": "2020-07-16T16:37:28.739Z", "status": "draft", "request_id": null, "disease": {"name": "Aggressive fibromatosis", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "CTNNB1", "name": "S45F", "hgvs_c": "ENST00000349496:c.134C>T", "hgvs_p": null, "reference_name": "GrCh37", "chromosome": "chr3", "start_pos": 41266137, "dbsnp_ids": null}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["sorafenib", "bafilomycin"], "interactions": [], "effect": "Sensitive (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Treatment of S45F-mutated primary desmoid tumor cells with a combination of sorafenib with bafilomycin led to a significant increase of cell death compared\nwith either sorafenib or bafilomycin alone.", "support": "Low", "comment": null, "references": "PMID:30980399", "annotations": [], "created_on": "2020-07-16T16:37:40.429Z", "last_modified": "2020-07-16T16:37:40.430Z", "status": "draft", "request_id": null, "disease": {"name": "Aggressive fibromatosis", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "CTNNB1", "name": "S45F", "hgvs_c": "ENST00000349496:c.134C>T", "hgvs_p": null, "reference_name": "GrCh37", "chromosome": "chr3", "start_pos": 41266137, "dbsnp_ids": null}, "extra_variants": []}, {"type_of_evidence": "Subcellular location", "drugs": [], "interactions": [], "effect": "Increased physiological location", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Nuclear localization of variant S45F was observed in an adrenal cortical carcinoma sample.", "support": "Moderate", "comment": null, "references": "PMID:29872083", "annotations": [], "created_on": "2020-08-07T15:30:11.790Z", "last_modified": "2020-08-07T15:30:11.791Z", "status": "draft", "request_id": null, "disease": {"name": "Adrenal cortical carcinoma", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "CTNNB1", "name": "S45F", "hgvs_c": "ENST00000349496:c.134C>T", "hgvs_p": null, "reference_name": "GrCh37", "chromosome": "chr3", "start_pos": 41266137, "dbsnp_ids": null}, "extra_variants": []}, {"type_of_evidence": "Prognostic", "drugs": [], "interactions": [], "effect": "Poor outcome", "tier_level_criteria": "Population study", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "In patients diagnosed with desmoid tumors, the estimated 3-year and 5-year recurrence-free survival (RFS) rates were 0.49 and 0.45, respectively, for patients who had tumors with the S45F mutation, and 0.91 and 0.91, respectively, for patients who had wild-type tumors. This also holds true for patients who underwent surgery, but there was no difference in RFS for patients who underwent surgery and received other treatments, such as radiotherapy, chemotherapy (frequently methotrexate and vinorelbine), medical therapy/hormone agents (tamoxifen, toremifene), and nonsteroidal anti-inflammatory drugs (cyclooxygenase-2 inhibitors).", "support": "Strong", "comment": "", "references": "PMID:23913621", "annotations": [], "created_on": "2020-07-13T09:52:21.929Z", "last_modified": "2020-08-13T14:41:39.202Z", "status": "draft", "request_id": null, "disease": {"name": "Aggressive fibromatosis", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "CTNNB1", "name": "S45F", "hgvs_c": "ENST00000349496:c.134C>T", "hgvs_p": null, "reference_name": "GrCh37", "chromosome": "chr3", "start_pos": 41266137, "dbsnp_ids": null}, "extra_variants": []}, {"type_of_evidence": "Variant identification", "drugs": [], "interactions": [], "effect": null, "tier_level_criteria": null, "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "The authors studied 220 hepatocellular carcinoma and 373 hepatocellular adenoma and observed equal distribution between both tumor types for alterations\nat residues T41 and S455. The variant at position 41 was almost exclusively T41A.", "support": "Strong", "comment": null, "references": "PMID:27177928", "annotations": [], "created_on": "2020-08-26T08:48:37.759Z", "last_modified": "2020-08-26T12:13:46.094Z", "status": "draft", "request_id": null, "disease": {"name": "Hepatocellular carcinoma", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "CTNNB1", "name": "T41A", "hgvs_c": "ENST00000349496:c.121A>G", "hgvs_p": null, "reference_name": "GrCh37", "chromosome": "chr3", "start_pos": 41266124, "dbsnp_ids": null}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["Imatinib"], "interactions": [], "effect": "Responsive", "tier_level_criteria": "Population study", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "The authors show a positive correlation of the CTNNB1 mutation status with the progression arrest rate after 6 months of therapy with imatinib.  The progression arrest rate (PAR) of 70 % could be demonstrated in patients with the T41A mutation, a PAR not as high as that observed for S45F mutation. Patients with wild-type CTNNB1 tumors exhibit a PAR of 43%. This observation supports imatinib as a viable treatment option in desmoid fibromatosis harboring CTNNB1 mutations. Caveat: only 10 patients bearing a T41A positive tumor.", "support": "Low", "comment": "", "references": "PMID:26861905", "annotations": [], "created_on": "2020-07-13T13:28:14.922Z", "last_modified": "2020-09-04T15:28:33.791Z", "status": "draft", "request_id": null, "disease": {"name": "Aggressive fibromatosis", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "CTNNB1", "name": "T41A", "hgvs_c": "ENST00000349496:c.121A>G", "hgvs_p": null, "reference_name": "GrCh37", "chromosome": "chr3", "start_pos": 41266124, "dbsnp_ids": null}, "extra_variants": []}, {"type_of_evidence": "Variant identification", "drugs": [], "interactions": [], "effect": null, "tier_level_criteria": null, "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "42% of CTNNB1-mutated hepatocellular adenomas (HCAs) in this study (55 tumors in total) exhibited association with IL6ST activating mutations. This association is especially striking in HCAs carrying T41 mutations, predominantly T41A, in which 89% of the tumors were also associated with IL6ST activating mutations.", "support": "Strong", "comment": "NOT DUPLICATE. This annotation describes association between 2 variants.", "references": "PMID:27177928", "annotations": [], "created_on": "2020-08-26T13:21:09.607Z", "last_modified": "2020-08-27T08:44:04.195Z", "status": "draft", "request_id": null, "disease": {"name": "Liver cell adenoma", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "CTNNB1", "name": "T41A", "hgvs_c": "ENST00000349496:c.121A>G", "hgvs_p": null, "reference_name": "GrCh37", "chromosome": "chr3", "start_pos": 41266124, "dbsnp_ids": null}, "extra_variants": []}, {"type_of_evidence": "Function", "drugs": [], "interactions": [], "effect": "Unaltered function", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "In 2 cohorts (a Dutch cohort: 11 tumors with exon 3 wild-type CTNNB1, 38 tumors with T41A variant and 12 with  S45F variant and a French cohort:  14 tumors with exon 3 wild-type CTNNB1, 45 tumors with T41A variant and 34 with  S45F variant), quantitative RT-PCR could not demonstrate any differential expression in selected Wnt target genes, including AXIN1, DKK1 and CCND1. There are several caveats in this study, including at least 1. definition of wild-type as lack of exon 3 mutations, and 2. selection of a subset of Wnt target genes.", "support": "Low", "comment": null, "references": "PMID:30528042", "annotations": [], "created_on": "2020-08-21T15:33:51.669Z", "last_modified": "2020-08-28T13:05:07.185Z", "status": "draft", "request_id": null, "disease": {"name": "Aggressive fibromatosis", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "CTNNB1", "name": "S45F", "hgvs_c": "ENST00000349496:c.134C>T", "hgvs_p": null, "reference_name": "GrCh37", "chromosome": "chr3", "start_pos": 41266137, "dbsnp_ids": null}, "extra_variants": []}, {"type_of_evidence": "Variant identification", "drugs": [], "interactions": [], "effect": null, "tier_level_criteria": null, "tier_level": null, "mutation_origin": "Germline", "associated_mendelian_diseases": "Li-Fraumeni syndrome", "summary": "Variant G245S was identified in a patient whose osteosarcoma was diagnosed at the age of 18 years. The family was classified as  having Li-Fraumeni-like syndrome by Eeles (1995)  (PMID:8718514).", "support": null, "comment": null, "references": "PMID:1565143", "annotations": [], "created_on": "2020-06-22T08:55:09.408Z", "last_modified": "2020-09-23T13:48:18.930Z", "status": "draft", "request_id": null, "disease": null, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "G245S", "hgvs_c": "NM_000546.5:c.733G>A", "hgvs_p": "NP_000537.3:p.Gly245Ser", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577548, "dbsnp_ids": ["28934575"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["AMGMDS3"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Assays performed in the rhabdomyosarcoma cell line RD, that  expresses variant R248W, show that the MDM2 inhibitor AMGMDS3 doesn't have any effect on cell proliferation.", "support": "Moderate", "comment": null, "references": "PMID:25730903", "annotations": [], "created_on": "2020-05-28T14:07:05.525Z", "last_modified": "2020-09-23T13:48:18.955Z", "status": "draft", "request_id": null, "disease": {"name": "Rhabdomyosarcoma", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R248W", "hgvs_c": "NM_000546.5:c.742C>T", "hgvs_p": "NP_000537.3:p.Arg248Trp", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577539, "dbsnp_ids": ["121912651"]}, "extra_variants": []}, {"type_of_evidence": "Subcellular location", "drugs": [], "interactions": [], "effect": "Unaltered location", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "As wild-type, variant R248W is located within the nucleus.", "support": "Strong", "comment": null, "references": "PMID:21187651", "annotations": [], "created_on": "2020-06-11T11:43:33.952Z", "last_modified": "2020-06-16T12:18:48.886Z", "status": "draft", "request_id": null, "disease": null, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R248W", "hgvs_c": "NM_000546.5:c.742C>T", "hgvs_p": "NP_000537.3:p.Arg248Trp", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577539, "dbsnp_ids": ["121912651"]}, "extra_variants": []}, {"type_of_evidence": "Variant identification", "drugs": [], "interactions": [], "effect": null, "tier_level_criteria": null, "tier_level": null, "mutation_origin": "Germline", "associated_mendelian_diseases": "Li-Fraumeni syndrome", "summary": null, "support": "Strong", "comment": null, "references": "PMID:1683921", "annotations": [], "created_on": "2020-06-15T18:55:11.799Z", "last_modified": "2020-09-23T13:48:18.909Z", "status": "draft", "request_id": null, "disease": null, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R248Q", "hgvs_c": "NM_000546.5:c.743G>A", "hgvs_p": "NP_000537.3:p.Arg248Gln", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577538, "dbsnp_ids": ["11540652"]}, "extra_variants": []}, {"type_of_evidence": "Variant identification", "drugs": [], "interactions": [], "effect": "Unknown", "tier_level_criteria": "None", "tier_level": null, "mutation_origin": "Germline", "associated_mendelian_diseases": "Li-Fraumeni syndrome", "summary": "Germline variant in Li-Fraumeni syndrome patients.", "support": null, "comment": null, "references": "PMID:8825920", "annotations": [], "created_on": "2020-05-19T16:40:20.304Z", "last_modified": "2020-09-23T13:48:18.916Z", "status": "draft", "request_id": null, "disease": null, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R175H", "hgvs_c": "NM_000546.5:c.524G>A", "hgvs_p": "NP_000537.3:p.Arg175His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7578406, "dbsnp_ids": ["28934578"]}, "extra_variants": []}, {"type_of_evidence": "Variant identification", "drugs": [], "interactions": [], "effect": null, "tier_level_criteria": null, "tier_level": null, "mutation_origin": "Germline", "associated_mendelian_diseases": "Li-Fraumeni syndrome", "summary": null, "support": "Strong", "comment": null, "references": "PMID:1565143", "annotations": [], "created_on": "2020-06-15T19:01:04.522Z", "last_modified": "2020-09-23T13:48:18.923Z", "status": "draft", "request_id": null, "disease": null, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R248Q", "hgvs_c": "NM_000546.5:c.743G>A", "hgvs_p": "NP_000537.3:p.Arg248Gln", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577538, "dbsnp_ids": ["11540652"]}, "extra_variants": []}, {"type_of_evidence": "Function", "drugs": [], "interactions": [], "effect": "Neomorphic", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "TP53 R248Q variant increases HER2/ERBB2 expression levels (at the mRNA and protein level) in various cell lines. The variant associates with chromatin and favors histone H3 and H4 acetylation in HER2 promoter proximal region.", "support": "Strong", "comment": null, "references": "PMID:29970031", "annotations": [], "created_on": "2020-06-10T13:42:49.983Z", "last_modified": "2020-09-23T13:48:18.965Z", "status": "draft", "request_id": null, "disease": {"name": "Ovarian Adenocarcinoma", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R248Q", "hgvs_c": "NM_000546.5:c.743G>A", "hgvs_p": "NP_000537.3:p.Arg248Gln", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577538, "dbsnp_ids": ["11540652"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["AMGMDS3"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Assays performed in Ewing\u2019s sarcoma cell line RD-ES, that  expresses variant R273C, show that the MDM2 inhibitor AMGMDS3 doesn't have any effect on cell proliferation.", "support": "Moderate", "comment": null, "references": "PMID:25730903", "annotations": [], "created_on": "2020-05-28T15:11:42.406Z", "last_modified": "2020-09-23T13:48:18.975Z", "status": "draft", "request_id": null, "disease": {"name": "Ewing\u2019S Sarcoma", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R273C", "hgvs_c": "NM_000546.5:c.817C>T", "hgvs_p": "NP_000537.3:p.Arg273Cys", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577121, "dbsnp_ids": ["121913343"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["AMGMDS3"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Assays performed in the ureter carcinoma cell line 639-V, that  expresses variant R248Q, show that the MDM2 inhibitor AMGMDS3 doesn't have any effect on cell proliferation.", "support": "Moderate", "comment": null, "references": "PMID:25730903", "annotations": [], "created_on": "2020-05-28T14:18:38.636Z", "last_modified": "2020-09-23T13:48:18.990Z", "status": "draft", "request_id": null, "disease": {"name": "Ureter Carcinoma", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R248Q", "hgvs_c": "NM_000546.5:c.743G>A", "hgvs_p": "NP_000537.3:p.Arg248Gln", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577538, "dbsnp_ids": ["11540652"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["AMGMDS3"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Assays performed in the epidermoid carcinoma cell line A431, that  expresses variant R273H, show that the MDM2 inhibitor AMGMDS3 doesn't have any effect on cell proliferation.", "support": "Moderate", "comment": null, "references": "PMID:25730903", "annotations": [], "created_on": "2020-05-28T15:23:08.795Z", "last_modified": "2020-09-23T13:48:19.000Z", "status": "draft", "request_id": null, "disease": {"name": "Epidermoid Carcinoma", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R273H", "hgvs_c": "NM_000546.5:c.818G>A", "hgvs_p": "NP_000537.3:p.Arg273His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577120, "dbsnp_ids": ["28934576"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["AMGMDS3"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Assays performed in the plasma cell leukemia cell line ARH-77, that  expresses variant R273H, show that the MDM2 inhibitor AMGMDS3 doesn't have any effect on cell proliferation.", "support": "Moderate", "comment": null, "references": "PMID:25730903", "annotations": [], "created_on": "2020-05-28T15:24:49.206Z", "last_modified": "2020-09-23T13:48:19.015Z", "status": "draft", "request_id": null, "disease": {"name": "Plasma Cell Leukemia", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R273H", "hgvs_c": "NM_000546.5:c.818G>A", "hgvs_p": "NP_000537.3:p.Arg273His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577120, "dbsnp_ids": ["28934576"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["AMGMDS3"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Assays performed in the leiomyosarcoma cell line SK-LMS-1, that  expresses variant G245S, show that the MDM2 inhibitor AMGMDS3 doesn't have any effect on cell proliferation.", "support": "Moderate", "comment": null, "references": "PMID:25730903", "annotations": [], "created_on": "2020-05-28T15:44:12.414Z", "last_modified": "2020-09-23T13:48:19.024Z", "status": "draft", "request_id": null, "disease": {"name": "Leiomyosarcoma", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "G245S", "hgvs_c": "NM_000546.5:c.733G>A", "hgvs_p": "NP_000537.3:p.Gly245Ser", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577548, "dbsnp_ids": ["28934575"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["AMGMDS3"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Assays performed in the Ewing\u2019s sarcoma cell line SK-NEP-1, that  expresses variant G245S, show that the MDM2 inhibitor AMGMDS3 doesn't have any effect on cell proliferation.", "support": "Moderate", "comment": null, "references": "PMID:25730903", "annotations": [], "created_on": "2020-05-28T15:50:33.470Z", "last_modified": "2020-09-23T13:48:19.033Z", "status": "draft", "request_id": null, "disease": {"name": "Ewing\u2019S Sarcoma", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "G245S", "hgvs_c": "NM_000546.5:c.733G>A", "hgvs_p": "NP_000537.3:p.Gly245Ser", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577548, "dbsnp_ids": ["28934575"]}, "extra_variants": []}, {"type_of_evidence": "Variant identification", "drugs": [], "interactions": [], "effect": null, "tier_level_criteria": null, "tier_level": null, "mutation_origin": "Germline", "associated_mendelian_diseases": "Li-Fraumeni syndrome", "summary": null, "support": "Strong", "comment": null, "references": "PMID:1565144", "annotations": [], "created_on": "2020-06-19T14:33:02.128Z", "last_modified": "2020-09-23T13:48:19.041Z", "status": "draft", "request_id": null, "disease": null, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R248W", "hgvs_c": "NM_000546.5:c.742C>T", "hgvs_p": "NP_000537.3:p.Arg248Trp", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577539, "dbsnp_ids": ["121912651"]}, "extra_variants": []}, {"type_of_evidence": "Variant identification", "drugs": [], "interactions": [], "effect": null, "tier_level_criteria": null, "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Identified in mucinous adenocarcinoma of the salivary gland. According to cBioPortal for Cancer Genomics (www.cbioportal.org),  R213X is the most frequent nonsense TP53 mutation in esophageal, kidney chromophobe, stomach, colorectal cancers, and melanoma with an average frequency of 3\u20134% . Note that treatment with G418, an aminoglycoside antibiotic, induces read-through of the c.637C > T mutation and expression of full-length p53.", "support": "Strong", "comment": null, "references": "PMID:28249646", "annotations": [], "created_on": "2020-06-22T13:27:18.472Z", "last_modified": "2020-09-23T13:48:19.055Z", "status": "draft", "request_id": null, "disease": {"name": "Mucinous Adenocarcinoma", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R213*", "hgvs_c": "ENST00000269305:c.637C>T", "hgvs_p": null, "reference_name": "GrCh37", "chromosome": "chr17", "start_pos": 7578212, "dbsnp_ids": null}, "extra_variants": []}, {"type_of_evidence": "Function", "drugs": [], "interactions": [], "effect": "Neomorphic", "tier_level_criteria": "Well-established in vivo study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Contrary to TP53-null cells, cells transfected with R248W variant form tumors in nude mice.", "support": "Strong", "comment": null, "references": "PMID:8099841", "annotations": [], "created_on": "2020-06-16T13:37:54.724Z", "last_modified": "2020-06-17T09:30:38.256Z", "status": "draft", "request_id": null, "disease": null, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R248W", "hgvs_c": "NM_000546.5:c.742C>T", "hgvs_p": "NP_000537.3:p.Arg248Trp", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577539, "dbsnp_ids": ["121912651"]}, "extra_variants": []}, {"type_of_evidence": "Function", "drugs": [], "interactions": [], "effect": "Loss of function", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "When analyzed in humanized primary mouse embryonic fibroblasts (MEFs), the G245S variant did not express any TP53 transcriptional activity, as indicated by nearly undetectable p21/CDKN1A mRNA and protein levels at baseline and on DNA damage. Similar to p53-null MEFs, G245S MEFs were immortal and their growth rates identical to null MEFs. Moreover, thymocytes were completely resistant to apoptosis after gamma-irradiation and failed to induce p21/CDKN1A, PUMA/BBC3 and cleaved caspase 3.", "support": "Strong", "comment": null, "references": "PMID:23538418", "annotations": [], "created_on": "2020-06-08T18:08:46.610Z", "last_modified": "2020-06-22T08:13:37.807Z", "status": "draft", "request_id": null, "disease": null, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "G245S", "hgvs_c": "NM_000546.5:c.733G>A", "hgvs_p": "NP_000537.3:p.Gly245Ser", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577548, "dbsnp_ids": ["28934575"]}, "extra_variants": []}, {"type_of_evidence": "Function", "drugs": [], "interactions": [], "effect": "Dominant negative", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "R248W mutant reduces the ability of the wild-type protein to suppress cell proliferation.", "support": "Strong", "comment": null, "references": "PMID:14743206", "annotations": [], "created_on": "2020-06-18T14:34:32.183Z", "last_modified": "2020-06-18T15:29:07.800Z", "status": "draft", "request_id": null, "disease": null, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R248W", "hgvs_c": "NM_000546.5:c.742C>T", "hgvs_p": "NP_000537.3:p.Arg248Trp", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577539, "dbsnp_ids": ["121912651"]}, "extra_variants": []}, {"type_of_evidence": "Function", "drugs": [], "interactions": [], "effect": "Loss of function", "tier_level_criteria": "Well-established in vivo study", "tier_level": null, "mutation_origin": "Germline", "associated_mendelian_diseases": null, "summary": "In humanized  G245S knockin mice, there is no evidence for gain of function, as G245S hetero- and homozygous animals were similar to null mice in tumor latency and survival. In humans, data collected in p53 IARC database (https://p53.iarc.fr/) show that patients heterozygous for G245S variant do not exhibit phenotypic difference as compared to patients heterozygous for null allele.", "support": "Strong", "comment": null, "references": "PMID:23538418", "annotations": [], "created_on": "2020-06-09T17:27:48.445Z", "last_modified": "2020-06-22T08:13:42.222Z", "status": "draft", "request_id": null, "disease": null, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "G245S", "hgvs_c": "NM_000546.5:c.733G>A", "hgvs_p": "NP_000537.3:p.Gly245Ser", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577548, "dbsnp_ids": ["28934575"]}, "extra_variants": []}, {"type_of_evidence": "Function", "drugs": [], "interactions": [], "effect": "Neomorphic", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "The expression of H175R variant promotes TGFB1-induced migration of cells (in knock-in mouse embryonic fibroblasts, as well as in transfected human H1299 cells), but only in cells expressing both mutant p53 and oncogenic HRAS variant G12V. This neomorphic response to TGFB1 is mediated by TP63  inactivation within a ternary complex formed by TP63, TP53 R175H variant and SMAD2 and may be due to the down-regulation of two TP63 target genes, BHLHE41/Sharp-1 and CCNG2/Cyclin G2. In breast cancer, low expression of these two genes may be associated with higher probability to develop recurrence and is associated to risk of distant metastasis to bone and lung.", "support": "Moderate", "comment": null, "references": "PMID:19345189", "annotations": [], "created_on": "2020-05-20T12:32:08.414Z", "last_modified": "2020-05-20T15:06:40.501Z", "status": "draft", "request_id": null, "disease": null, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R175H", "hgvs_c": "NM_000546.5:c.524G>A", "hgvs_p": "NP_000537.3:p.Arg175His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7578406, "dbsnp_ids": ["28934578"]}, "extra_variants": []}, {"type_of_evidence": "Function", "drugs": [], "interactions": [], "effect": "Loss of function", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "When analyzed in humanized primary mouse embryonic fibroblasts (MEFs), the R248Q variant did not express any TP53 transcriptional activity, as indicated by nearly undetectable p21/CDKN1A mRNA and protein levels at baseline and on DNA damage. Similar to p53-null MEFs, R248Q MEFs were immortal and their growth rates identical to null MEFs. Moreover, thymocytes were completely resistant to apoptosis after gamma-irradiation and failed to induce p21/CDKN1A, PUMA/BBC3 and cleaved caspase 3.", "support": "Strong", "comment": null, "references": "PMID:23538418", "annotations": [], "created_on": "2020-06-08T18:11:00.953Z", "last_modified": "2020-06-12T17:02:24.663Z", "status": "draft", "request_id": null, "disease": null, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R248Q", "hgvs_c": "NM_000546.5:c.743G>A", "hgvs_p": "NP_000537.3:p.Arg248Gln", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577538, "dbsnp_ids": ["11540652"]}, "extra_variants": []}, {"type_of_evidence": "Function", "drugs": [], "interactions": [], "effect": "Loss of function", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Contrary to wild-type p53, variant R248W does not induce the expression of  CDKN1A/p21.", "support": "Strong", "comment": null, "references": "PMID:14743206", "annotations": [], "created_on": "2020-06-18T15:10:04.002Z", "last_modified": "2020-06-18T15:29:11.153Z", "status": "draft", "request_id": null, "disease": null, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R248W", "hgvs_c": "NM_000546.5:c.742C>T", "hgvs_p": "NP_000537.3:p.Arg248Trp", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577539, "dbsnp_ids": ["121912651"]}, "extra_variants": []}, {"type_of_evidence": "Function", "drugs": [], "interactions": [], "effect": "Dominant negative", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Dominant negative when tested in a yeast functional assay (FASAY).", "support": "Low", "comment": null, "references": "PMID:27589690", "annotations": [], "created_on": "2020-05-29T09:15:09.791Z", "last_modified": "2020-06-22T08:13:32.531Z", "status": "draft", "request_id": null, "disease": null, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "G245S", "hgvs_c": "NM_000546.5:c.733G>A", "hgvs_p": "NP_000537.3:p.Gly245Ser", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577548, "dbsnp_ids": ["28934575"]}, "extra_variants": []}, {"type_of_evidence": "Function", "drugs": [], "interactions": [], "effect": "Loss of function", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "When tested in TP53-null Saos cells, R248W was unable to inhibit growth, contrary to wild-type TP53.", "support": "Moderate", "comment": null, "references": "PMID:1631137", "annotations": [], "created_on": "2020-06-22T15:10:16.211Z", "last_modified": "2020-06-22T15:14:41.580Z", "status": "draft", "request_id": null, "disease": null, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R248W", "hgvs_c": "NM_000546.5:c.742C>T", "hgvs_p": "NP_000537.3:p.Arg248Trp", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577539, "dbsnp_ids": ["121912651"]}, "extra_variants": []}, {"type_of_evidence": "Interaction", "drugs": [], "interactions": ["ETS2"], "effect": "New interaction partner(s)", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Co-immunoprecipitations were performed in transfected HEK293T cells.", "support": "Low", "comment": null, "references": "PMID:26331536", "annotations": [], "created_on": "2020-05-22T15:40:05.065Z", "last_modified": "2020-05-25T09:04:32.346Z", "status": "draft", "request_id": null, "disease": null, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R273H", "hgvs_c": "NM_000546.5:c.818G>A", "hgvs_p": "NP_000537.3:p.Arg273His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577120, "dbsnp_ids": ["28934576"]}, "extra_variants": []}, {"type_of_evidence": "Function", "drugs": [], "interactions": [], "effect": "Neomorphic", "tier_level_criteria": "Well-established in vivo study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Contrary to TP53-null cells, cells transfected with R273H variant form tumors in nude mice.", "support": "Strong", "comment": null, "references": "PMID:8099841", "annotations": [], "created_on": "2020-06-17T09:46:07.937Z", "last_modified": "2020-06-17T09:46:07.937Z", "status": "draft", "request_id": null, "disease": null, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R273H", "hgvs_c": "NM_000546.5:c.818G>A", "hgvs_p": "NP_000537.3:p.Arg273His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577120, "dbsnp_ids": ["28934576"]}, "extra_variants": []}, {"type_of_evidence": "Interaction", "drugs": [], "interactions": ["ETS2"], "effect": "New interaction partner(s)", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Binding assays were conducted in transfected HEK293T cells, as well as with purified proteins, indicating direct interaction.", "support": "Strong", "comment": null, "references": "PMID:26331536", "annotations": [], "created_on": "2020-05-20T07:46:20.511Z", "last_modified": "2020-05-20T09:40:09.231Z", "status": "draft", "request_id": null, "disease": null, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R175H", "hgvs_c": "NM_000546.5:c.524G>A", "hgvs_p": "NP_000537.3:p.Arg175His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7578406, "dbsnp_ids": ["28934578"]}, "extra_variants": []}, {"type_of_evidence": "Function", "drugs": [], "interactions": [], "effect": "Dominant negative", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Mutant R175H reduces the ability of wild-type p53 to transactivate its target genes, including CDKN1A/p21, TP53I3/PIG3, FDXR and MDM2. It exerts its dominant negative effect by reducing the ability of the wild-type protein to bind to the p53 responsive element in its target genes, and consequently its transcriptional activity.", "support": "Strong", "comment": null, "references": "PMID:14743206", "annotations": [], "created_on": "2020-06-18T14:32:21.682Z", "last_modified": "2020-06-18T15:28:32.692Z", "status": "draft", "request_id": null, "disease": null, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R175H", "hgvs_c": "NM_000546.5:c.524G>A", "hgvs_p": "NP_000537.3:p.Arg175His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7578406, "dbsnp_ids": ["28934578"]}, "extra_variants": []}, {"type_of_evidence": "Function", "drugs": [], "interactions": [], "effect": "Neomorphic", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "When tested in cell culture, R273H was able to activate transcription from the promoter region of multiple resistance protein ABCB1.", "support": "Moderate", "comment": null, "references": "PMID:8099841", "annotations": [], "created_on": "2020-06-17T09:44:45.426Z", "last_modified": "2020-06-17T09:46:19.050Z", "status": "draft", "request_id": null, "disease": null, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R273H", "hgvs_c": "NM_000546.5:c.818G>A", "hgvs_p": "NP_000537.3:p.Arg273His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577120, "dbsnp_ids": ["28934576"]}, "extra_variants": []}, {"type_of_evidence": "Function", "drugs": [], "interactions": [], "effect": "Neomorphic", "tier_level_criteria": "Well-established in vivo study", "tier_level": null, "mutation_origin": "Germline", "associated_mendelian_diseases": null, "summary": "Compared with TP53-null mice, humanized R248Q knockin mice had accelerated onset of all tumor types (T lymphomas, B lymphomas and solid tumors) and shorter survival. In these animals, R248Q lymphomas show enhanced proliferation and signaling through the Akt pathway in vivo, but not in vitro, compared to TP53-null lymphomas. Cell lines deriving from these R248Q lymphoma develop into highly aggressive leukemias in vivo. In humans, data collected in p53 IARC database (https://p53.iarc.fr/) show that patients heterozygous for R248Q variant have a drastically younger median age by over 10 years until first tumor onset compared with patients with a null/+ genotype (R248Q/+, 19.5 years; null/+, 30 years). In addition, up to the sixth decade of life, the cumulative number of tumors reported per person at risk was also higher than for null allele patients.", "support": "Strong", "comment": null, "references": "PMID:23538418", "annotations": [], "created_on": "2020-06-09T18:01:12.442Z", "last_modified": "2020-06-12T17:01:49.356Z", "status": "draft", "request_id": null, "disease": null, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R248Q", "hgvs_c": "NM_000546.5:c.743G>A", "hgvs_p": "NP_000537.3:p.Arg248Gln", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577538, "dbsnp_ids": ["11540652"]}, "extra_variants": []}, {"type_of_evidence": "Function", "drugs": [], "interactions": [], "effect": "Dominant negative", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": null, "support": "Low", "comment": null, "references": "PMID:27589690", "annotations": [], "created_on": "2020-05-29T08:33:41.222Z", "last_modified": "2020-05-29T09:15:37.915Z", "status": "draft", "request_id": null, "disease": null, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R175H", "hgvs_c": "NM_000546.5:c.524G>A", "hgvs_p": "NP_000537.3:p.Arg175His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7578406, "dbsnp_ids": ["28934578"]}, "extra_variants": []}, {"type_of_evidence": "Interaction", "drugs": [], "interactions": [], "effect": "New interaction partner(s)", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "TGFB1 induces the formation of the ternary complex between TP63, TP53 R175H variant and SMAD2 in presence of oncogenic HRAS variant G12V. The formation of this complex requires mutant TP53 N-terminal phosphorylation by HRAS. TP63 transcriptional activity is inhibited within this complex.", "support": "Moderate", "comment": null, "references": "PMID:19345189", "annotations": [], "created_on": "2020-05-20T13:24:09.421Z", "last_modified": "2020-05-20T15:06:34.913Z", "status": "draft", "request_id": null, "disease": null, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R175H", "hgvs_c": "NM_000546.5:c.524G>A", "hgvs_p": "NP_000537.3:p.Arg175His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7578406, "dbsnp_ids": ["28934578"]}, "extra_variants": []}, {"type_of_evidence": "Response to drug", "drugs": ["OICR-9429"], "interactions": [], "effect": "Newly acquired drug response", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "In MDAH087 cell line (skin fibroblasts from a Li-Fraumeni syndrome patient), OICR-9429 treatment inhibits R248W-dependent cell growth. OICR-9429 is an  antagonist of the interaction between WDR5 and KMT2A/ MLL1.", "support": "Moderate", "comment": null, "references": "PMID:26331536", "annotations": [], "created_on": "2020-05-26T12:08:28.229Z", "last_modified": "2020-05-26T12:22:29.104Z", "status": "draft", "request_id": null, "disease": null, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R248W", "hgvs_c": "NM_000546.5:c.742C>T", "hgvs_p": "NP_000537.3:p.Arg248Trp", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577539, "dbsnp_ids": ["121912651"]}, "extra_variants": []}, {"type_of_evidence": "Function", "drugs": [], "interactions": [], "effect": "Dominant negative", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "When tested in a yeast assay, G245S shows a dominant negative effect.", "support": "Moderate", "comment": null, "references": "PMID:8633021", "annotations": [], "created_on": "2020-06-22T15:27:25.954Z", "last_modified": "2020-06-22T15:31:34.092Z", "status": "draft", "request_id": null, "disease": null, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "G245S", "hgvs_c": "NM_000546.5:c.733G>A", "hgvs_p": "NP_000537.3:p.Gly245Ser", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577548, "dbsnp_ids": ["28934575"]}, "extra_variants": []}, {"type_of_evidence": "Response to drug", "drugs": ["OICR-9429"], "interactions": [], "effect": "Newly acquired drug response", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Knock-in mouse embryonic fibroblasts exhibit decreased cell proliferation in the presence of OICR-9429, an antagonist of the interaction between WDR5 and KMT2A/ MLL1.", "support": "Moderate", "comment": null, "references": "PMID:26331536", "annotations": [], "created_on": "2020-05-22T15:31:49.332Z", "last_modified": "2020-05-26T12:22:54.679Z", "status": "draft", "request_id": null, "disease": null, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R175H", "hgvs_c": "NM_000546.5:c.524G>A", "hgvs_p": "NP_000537.3:p.Arg175His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7578406, "dbsnp_ids": ["28934578"]}, "extra_variants": []}, {"type_of_evidence": "Function", "drugs": [], "interactions": [], "effect": "Neomorphic", "tier_level_criteria": "Well-established in vivo study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Contrary to TP53-null cells, cells transfected with R175H variant form tumors in nude mice.", "support": "Strong", "comment": null, "references": "PMID:8099841", "annotations": [], "created_on": "2020-06-17T09:30:15.718Z", "last_modified": "2020-06-17T09:30:15.719Z", "status": "draft", "request_id": null, "disease": null, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R175H", "hgvs_c": "NM_000546.5:c.524G>A", "hgvs_p": "NP_000537.3:p.Arg175His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7578406, "dbsnp_ids": ["28934578"]}, "extra_variants": []}, {"type_of_evidence": "Interaction", "drugs": [], "interactions": ["ETS2"], "effect": "New interaction partner(s)", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Binding to ETS2 was studied by co-immunoprecipitation in transfected HEK293T cells.", "support": "Strong", "comment": null, "references": "PMID:26331536", "annotations": [], "created_on": "2020-05-22T15:38:25.511Z", "last_modified": "2020-06-16T13:11:02.496Z", "status": "draft", "request_id": null, "disease": null, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R248W", "hgvs_c": "NM_000546.5:c.742C>T", "hgvs_p": "NP_000537.3:p.Arg248Trp", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577539, "dbsnp_ids": ["121912651"]}, "extra_variants": []}, {"type_of_evidence": "Function", "drugs": [], "interactions": [], "effect": "Loss of function", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Loss of transcription activation of CDKN1A (also called p21 CIP1 or WAF1) gene and of growth arrest in response to TGFB1 in transfected human H1299 cells.", "support": "Strong", "comment": null, "references": "PMID:19345189", "annotations": [], "created_on": "2020-05-20T12:44:21.510Z", "last_modified": "2020-05-20T15:06:37.467Z", "status": "draft", "request_id": null, "disease": null, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R175H", "hgvs_c": "NM_000546.5:c.524G>A", "hgvs_p": "NP_000537.3:p.Arg175His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7578406, "dbsnp_ids": ["28934578"]}, "extra_variants": []}, {"type_of_evidence": "Interaction", "drugs": [], "interactions": ["ETS2"], "effect": "New interaction partner(s)", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Co-immunoprecipitations were performed in transfected HEK293T cells", "support": "Moderate", "comment": null, "references": "PMID:26331536", "annotations": [], "created_on": "2020-05-22T15:36:33.455Z", "last_modified": "2020-05-22T15:36:33.456Z", "status": "draft", "request_id": null, "disease": null, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R248Q", "hgvs_c": "NM_000546.5:c.743G>A", "hgvs_p": "NP_000537.3:p.Arg248Gln", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577538, "dbsnp_ids": ["11540652"]}, "extra_variants": []}, {"type_of_evidence": "Function", "drugs": [], "interactions": [], "effect": "Neomorphic", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "When tested in cell culture, R248W was able to activate transcription from the promoter region of multiple resistance protein ABCB1.", "support": "Moderate", "comment": null, "references": "PMID:8099841", "annotations": [], "created_on": "2020-06-17T09:01:07.362Z", "last_modified": "2020-06-17T09:30:45.455Z", "status": "draft", "request_id": null, "disease": null, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R248W", "hgvs_c": "NM_000546.5:c.742C>T", "hgvs_p": "NP_000537.3:p.Arg248Trp", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577539, "dbsnp_ids": ["121912651"]}, "extra_variants": []}, {"type_of_evidence": "Function", "drugs": [], "interactions": [], "effect": "Neomorphic", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": "Germline", "associated_mendelian_diseases": null, "summary": "In the MDAH087 cell line originating from skin fibroblasts from a Li-Fraumeni syndrome patient, R248W variant was shown to up-regulate chromatin regulatory genes, including methyltransferases KMT2A/MLL1, KMT2D/MLL2, and acetyltransferase KAT6A/MOZ, resulting in a genome-wide increase of histone methylation and acetylation, that may provide cancer cells with a selective growth advantage. This neomorphic function is dependent upon EST2-binding.", "support": null, "comment": null, "references": "PMID:26331536", "annotations": [], "created_on": "2020-05-25T09:50:19.572Z", "last_modified": "2020-06-16T12:55:52.829Z", "status": "draft", "request_id": null, "disease": null, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R248W", "hgvs_c": "NM_000546.5:c.742C>T", "hgvs_p": "NP_000537.3:p.Arg248Trp", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577539, "dbsnp_ids": ["121912651"]}, "extra_variants": []}, {"type_of_evidence": "Function", "drugs": [], "interactions": [], "effect": "Dominant negative", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "When tested in yeast by FASAY, variant R248Q reduces transcription activation from p21/CDKN1A and RGC (ribosomal gene cluster) TP53-responsive promoters by wild-type TP53.", "support": "Low", "comment": null, "references": "PMID:27589690", "annotations": [], "created_on": "2020-05-29T09:43:51.288Z", "last_modified": "2020-06-12T17:20:16.709Z", "status": "draft", "request_id": null, "disease": null, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R248Q", "hgvs_c": "NM_000546.5:c.743G>A", "hgvs_p": "NP_000537.3:p.Arg248Gln", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577538, "dbsnp_ids": ["11540652"]}, "extra_variants": []}, {"type_of_evidence": "Function", "drugs": [], "interactions": [], "effect": "Loss of function", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "When tested in yeast by FASAY, variant R248Q shows loss of TP53-specific DNA-binding ability.", "support": "Moderate", "comment": null, "references": "PMID:21187651", "annotations": [], "created_on": "2020-06-11T11:00:41.340Z", "last_modified": "2020-06-11T13:35:03.698Z", "status": "draft", "request_id": null, "disease": null, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R248Q", "hgvs_c": "NM_000546.5:c.743G>A", "hgvs_p": "NP_000537.3:p.Arg248Gln", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577538, "dbsnp_ids": ["11540652"]}, "extra_variants": []}, {"type_of_evidence": "Response to drug", "drugs": ["MI-2-2"], "interactions": [], "effect": "Newly acquired drug response", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": "Germline", "associated_mendelian_diseases": null, "summary": "In MDAH087 cell line (skin fibroblasts from a Li-Fraumeni syndrome patient), MI-2-2 treatment inhibits R248W-dependent cell growth. MI-2-2 is a menin/MEN1 antagonist.", "support": "Moderate", "comment": null, "references": "PMID:26331536", "annotations": [], "created_on": "2020-05-25T10:33:12.787Z", "last_modified": "2020-06-16T12:55:02.475Z", "status": "draft", "request_id": null, "disease": null, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R248W", "hgvs_c": "NM_000546.5:c.742C>T", "hgvs_p": "NP_000537.3:p.Arg248Trp", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577539, "dbsnp_ids": ["121912651"]}, "extra_variants": []}, {"type_of_evidence": "Function", "drugs": [], "interactions": [], "effect": "Loss of function", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "When tested in yeast by FASAY, variant R248Q does not activate transcription from p21/CDKN1A and RGC (ribosomal gene cluster) TP53-responsive promoters.", "support": "Moderate", "comment": null, "references": "PMID:27589690", "annotations": [], "created_on": "2020-05-29T09:41:02.450Z", "last_modified": "2020-06-12T17:18:50.917Z", "status": "draft", "request_id": null, "disease": null, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R248Q", "hgvs_c": "NM_000546.5:c.743G>A", "hgvs_p": "NP_000537.3:p.Arg248Gln", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577538, "dbsnp_ids": ["11540652"]}, "extra_variants": []}, {"type_of_evidence": "Function", "drugs": [], "interactions": [], "effect": "Neomorphic", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "TP53 R273C variant increases HER2/ERBB2 expression levels (at the mRNA and protein level) in various cell lines. The variant associates with chromatin and favors histone H3 and H4 acetylation in HER2 promoter proximal region.", "support": "Strong", "comment": null, "references": "PMID:29970031", "annotations": [], "created_on": "2020-06-10T13:40:39.826Z", "last_modified": "2020-06-10T16:11:06.372Z", "status": "draft", "request_id": null, "disease": null, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R273C", "hgvs_c": "NM_000546.5:c.817C>T", "hgvs_p": "NP_000537.3:p.Arg273Cys", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577121, "dbsnp_ids": ["121913343"]}, "extra_variants": []}, {"type_of_evidence": "Function", "drugs": [], "interactions": [], "effect": "Neomorphic", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "H1299 cells transfected with R248Q variant show a higher invasive activity compared to parent cells, when tested in a Matrigel or a type I collagen invasion assay.", "support": "Low", "comment": null, "references": "PMID:21187651", "annotations": [], "created_on": "2020-06-11T12:01:13.241Z", "last_modified": "2020-06-11T12:02:58.600Z", "status": "draft", "request_id": null, "disease": null, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R248Q", "hgvs_c": "NM_000546.5:c.743G>A", "hgvs_p": "NP_000537.3:p.Arg248Gln", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577538, "dbsnp_ids": ["11540652"]}, "extra_variants": []}, {"type_of_evidence": "Function", "drugs": [], "interactions": [], "effect": "Neomorphic", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "In knock-in mouse embryonic fibroblasts, R172H variant (corresponding to human R175H) was shown to up-regulate chromatin regulatory genes, including methyltransferases KMT2A/MLL1, KMT2D/MLL2, and acetyltransferase KAT6A/MOZ, resulting in a genome-wide increase of histone methylation and acetylation, that may provide cancer cells with a selective growth advantage. This neomorphic function is dependent upon EST2-binding.", "support": "Strong", "comment": null, "references": "PMID:26331536", "annotations": [], "created_on": "2020-05-20T08:27:36.212Z", "last_modified": "2020-05-25T09:54:47.447Z", "status": "draft", "request_id": null, "disease": null, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R175H", "hgvs_c": "NM_000546.5:c.524G>A", "hgvs_p": "NP_000537.3:p.Arg175His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7578406, "dbsnp_ids": ["28934578"]}, "extra_variants": []}, {"type_of_evidence": "Function", "drugs": [], "interactions": [], "effect": "Dominant negative", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "When tested in a yeast assay, R248W shows a dominant negative effect.", "support": "Moderate", "comment": null, "references": "PMID:8633021", "annotations": [], "created_on": "2020-06-22T15:25:56.396Z", "last_modified": "2020-06-22T15:31:28.985Z", "status": "draft", "request_id": null, "disease": null, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R248W", "hgvs_c": "NM_000546.5:c.742C>T", "hgvs_p": "NP_000537.3:p.Arg248Trp", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577539, "dbsnp_ids": ["121912651"]}, "extra_variants": []}, {"type_of_evidence": "Function", "drugs": [], "interactions": [], "effect": "Neomorphic", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "When tested in cell culture, R175H was able to activate transcription from the promoter region of multiple resistance protein ABCB1.", "support": "Moderate", "comment": null, "references": "PMID:8099841", "annotations": [], "created_on": "2020-06-17T09:23:36.184Z", "last_modified": "2020-06-17T09:23:36.184Z", "status": "draft", "request_id": null, "disease": null, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R175H", "hgvs_c": "NM_000546.5:c.524G>A", "hgvs_p": "NP_000537.3:p.Arg175His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7578406, "dbsnp_ids": ["28934578"]}, "extra_variants": []}, {"type_of_evidence": "Function", "drugs": [], "interactions": [], "effect": "Loss of function", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": null, "support": "Moderate", "comment": null, "references": "PMID:27589690", "annotations": [], "created_on": "2020-05-29T08:31:30.392Z", "last_modified": "2020-05-29T08:49:17.166Z", "status": "draft", "request_id": null, "disease": null, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R175H", "hgvs_c": "NM_000546.5:c.524G>A", "hgvs_p": "NP_000537.3:p.Arg175His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7578406, "dbsnp_ids": ["28934578"]}, "extra_variants": []}, {"type_of_evidence": "Function", "drugs": [], "interactions": [], "effect": "Loss of function", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "When tested in yeast by FASAY, variant R248W shows loss of TP53-specific DNA-binding ability.", "support": "Moderate", "comment": null, "references": "PMID:21187651", "annotations": [], "created_on": "2020-06-11T11:01:09.159Z", "last_modified": "2020-06-11T13:35:41.916Z", "status": "draft", "request_id": null, "disease": null, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R248W", "hgvs_c": "NM_000546.5:c.742C>T", "hgvs_p": "NP_000537.3:p.Arg248Trp", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577539, "dbsnp_ids": ["121912651"]}, "extra_variants": []}, {"type_of_evidence": "Function", "drugs": [], "interactions": [], "effect": "Loss of function", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Contrary to wild-type p53, variant R273H does not induce the expression of  CDKN1A/p21.", "support": "Strong", "comment": null, "references": "PMID:14743206", "annotations": [], "created_on": "2020-06-18T15:10:08.507Z", "last_modified": "2020-06-18T15:29:48.605Z", "status": "draft", "request_id": null, "disease": null, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R273H", "hgvs_c": "NM_000546.5:c.818G>A", "hgvs_p": "NP_000537.3:p.Arg273His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577120, "dbsnp_ids": ["28934576"]}, "extra_variants": []}, {"type_of_evidence": "Function", "drugs": [], "interactions": [], "effect": "Loss of function", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": null, "support": "Moderate", "comment": null, "references": "PMID:27589690", "annotations": [], "created_on": "2020-05-29T09:51:33.048Z", "last_modified": "2020-05-29T09:51:33.049Z", "status": "draft", "request_id": null, "disease": null, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R273H", "hgvs_c": "NM_000546.5:c.818G>A", "hgvs_p": "NP_000537.3:p.Arg273His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577120, "dbsnp_ids": ["28934576"]}, "extra_variants": []}, {"type_of_evidence": "Function", "drugs": [], "interactions": [], "effect": "Loss of function", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Loss of function when tested in a yeast functional assay (FASAY).", "support": "Moderate", "comment": null, "references": "PMID:27589690", "annotations": [], "created_on": "2020-05-29T09:14:19.308Z", "last_modified": "2020-06-22T08:13:29.872Z", "status": "draft", "request_id": null, "disease": null, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "G245S", "hgvs_c": "NM_000546.5:c.733G>A", "hgvs_p": "NP_000537.3:p.Gly245Ser", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577548, "dbsnp_ids": ["28934575"]}, "extra_variants": []}, {"type_of_evidence": "Function", "drugs": [], "interactions": [], "effect": "Dominant negative", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Mutant R273H reduces the ability of wild-type p53 to transactivate its target genes, including CDKN1A/p21, TP53I3/PIG3, FDXR and MDM2. It exerts its dominant negative effect by reducing the ability of the wild-type protein to bind to the p53 responsive element in its target genes, and consequently its transcriptional activity.", "support": "Strong", "comment": null, "references": "PMID:14743206", "annotations": [], "created_on": "2020-06-18T14:30:34.225Z", "last_modified": "2020-06-18T15:33:05.614Z", "status": "draft", "request_id": null, "disease": null, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "TP53", "name": "R273H", "hgvs_c": "NM_000546.5:c.818G>A", "hgvs_p": "NP_000537.3:p.Arg273His", "reference_name": "GRCh37", "chromosome": "17", "start_pos": 7577120, "dbsnp_ids": ["28934576"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["Oxaliplatin"], "interactions": [], "effect": "Not responsive", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Patient\u2011derived colon cancer xenografts (PDCCX) were grown in mice. Compared with the parental human tumors, PDCCX tumors maintained the original histological characteristics. One of these tumors carried a double mutation CTNNB1 T41A and BRAF V600E. Its growth was not affected by oxaliplatin.", "support": "Low", "comment": null, "references": "PMID:29541216", "annotations": [], "created_on": "2020-08-26T14:44:44.544Z", "last_modified": "2020-09-23T13:48:19.126Z", "status": "draft", "request_id": null, "disease": {"name": "Adenocarcinoma of colorectum", "localization": "COLON", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "CTNNB1", "name": "T41A", "hgvs_c": "ENST00000349496:c.121A>G", "hgvs_p": null, "reference_name": "GrCh37", "chromosome": "chr3", "start_pos": 41266124, "dbsnp_ids": null}, "extra_variants": [{"gene__symbol": "BRAF", "name": "V600E", "hgvs_c": "NM_004333.4:c.1799T>A"}]}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["Cetuximab"], "interactions": [], "effect": "Not responsive", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Patient\u2011derived colon cancer xenografts (PDCCX) were grown in mice. Compared with the parental human tumors, PDCCX tumors maintained the original histological characteristics. One of these tumors carried a double mutation CTNNB1 T41A and BRAF V600E. Its growth was not affected by cetuximab.", "support": "Low", "comment": null, "references": "PMID:29541216", "annotations": [], "created_on": "2020-08-26T14:46:43.798Z", "last_modified": "2020-09-23T13:48:19.137Z", "status": "draft", "request_id": null, "disease": {"name": "Adenocarcinoma of colorectum", "localization": "COLON", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "CTNNB1", "name": "T41A", "hgvs_c": "ENST00000349496:c.121A>G", "hgvs_p": null, "reference_name": "GrCh37", "chromosome": "chr3", "start_pos": 41266124, "dbsnp_ids": null}, "extra_variants": [{"gene__symbol": "BRAF", "name": "V600E", "hgvs_c": "NM_004333.4:c.1799T>A"}]}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["Fluorouracil"], "interactions": [], "effect": "Not responsive", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Patient\u2011derived colon cancer xenografts (PDCCX) were grown in mice. Compared with the parental human tumors, PDCCX tumors maintained the original histological characteristics. One of these tumors carried a double mutation CTNNB1 T41A and BRAF V600E. Its growth was not affected by 5-fluorouracil.", "support": "Low", "comment": null, "references": "PMID:29541216", "annotations": [], "created_on": "2020-08-26T14:50:05.011Z", "last_modified": "2020-09-23T13:48:19.148Z", "status": "draft", "request_id": null, "disease": {"name": "Adenocarcinoma of colorectum", "localization": "COLON", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "CTNNB1", "name": "T41A", "hgvs_c": "ENST00000349496:c.121A>G", "hgvs_p": null, "reference_name": "GrCh37", "chromosome": "chr3", "start_pos": 41266124, "dbsnp_ids": null}, "extra_variants": [{"gene__symbol": "BRAF", "name": "V600E", "hgvs_c": "NM_004333.4:c.1799T>A"}]}]